

BMJ Open - Decision on Manuscript ID bmjopen-2016-014332

36 messages

BMJ Open <onbehalf+info.bmjopen+bmj.com@manuscriptcentral.com>

Tue, Jan 10, 2017 at 10:31 PM

Reply-To: info.bmjopen@bmj.com

To: wwariki@gmail.com, wwariki@yahoo.com

Cc: wwariki@gmail.com, wwariki@yahoo.com, ota@slcn.ac.jp, rintaromori@gmail.com, charles.wiysonge@mrc.ac.za, Nosicelo.Mchiza@mrc.ac.za, Hacsi.Horvath@ucsf.edu, Jennifer.Read@ucsf.edu

10-Jan-2017

Dear Dr. Wariki,

Manuscript ID bmjopen-2016-014332 entitled "Interventions for preventing mother-to-child HIV transmission: Protocol of an overview of systematic reviews" which you submitted to BMJ Open, has been reviewed. The comments of the reviewers are included at the bottom of this letter.

The reviewers have recommended revisions to your manuscript. Therefore, I invite you to respond to the reviewers' comments and revise your manuscript. Please remember that the reviewers' comments and the previous drafts of your manuscript will be published as supplementary information alongside the final version.

In addition to the above, please address the editorial requests towards the end of this letter.

To revise your manuscript, log into <https://mc.manuscriptcentral.com/bmjopen> and enter your Author Center, where you will find your manuscript title listed under "Manuscripts with Decisions." Under "Actions," click on "Create a Revision." Your manuscript number has been appended to denote a revision.

You may also click the below link to start the revision process (or continue the process if you have already started your revision) for your manuscript. If you use the below link you will not be required to login to ScholarOne Manuscripts.

*** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. ***

https://mc.manuscriptcentral.com/bmjopen?URL_MASK=7454362144674380b4d3434862e66609

You will be unable to make your revisions on the originally submitted version of the manuscript. Instead, revise your manuscript using a word processing program and save it on your computer. Please also highlight the changes to your manuscript within the document by using the track changes mode in MS Word or by using bold or colored text. Once the revised manuscript is prepared, you can upload it and submit it through your Author Center.

When submitting your revised manuscript, you will be able to respond to the comments made by the reviewer(s) in the space provided. You can use this space to document any changes you make to the original manuscript. In order to expedite the processing of the revised manuscript, please be as specific as possible in your response to the reviewer(s).

You will receive a proof if your article is accepted, but you will be unable to make substantial changes to your manuscript, please take this opportunity to check the revised submission carefully.

IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission.

Because we are trying to facilitate timely publication of manuscripts submitted to BMJ Open, your revised manuscript should be submitted within 28 days. If it is not possible for you to submit your revision by this date, we may have to consider your paper as a new submission.

Once again, thank you for submitting your manuscript to BMJ Open and I look forward to receiving your revision.

Sincerely,

Dr Edward Sucksmith
BMJ Open Managing Editor
esucksmith@bmj.com

Editorial Requests:

- Please add 1 or 2 limitations to the 'Strengths and Limitations' section on pages 4-5. This section should contain up to five short bullet points, no longer than one sentence each, that ideally relate to the methods of the study reported (see: <http://bmjopen.bmj.com/site/about/guidelines.xhtml#articletypes>).

- Please improve the reporting of your methods e.g. what dates will the literature be searched? What key terms will be used? Please include a draft of the full search strategy for at least one database as a supplementary file.

- Please include an 'ethics and dissemination' section after the methods and analysis, as per journal requirements for study protocols (see: <http://bmjopen.bmj.com/site/about/guidelines.xhtml#studyprotocols>).

- Along with your revised manuscript, please provide a completed copy of the PRISMA-P checklist (<http://www.prisma-statement.org/documents/PRISMA-P-checklist.pdf>). Please remember to include the relevant page number(s) from the manuscript next to each reporting item or state 'n/a' next to items that are not applicable to your study.

Reviewers' Comments to Author:

Reviewer: 1

Reviewer Name: Alison Drake

Institution and Country: Assistant Professor, University of Washington, USE

Competing Interests: 'None declared'

This manuscript describes the protocol the investigators plan to use to summarize systematic review on prevention of mother-to-child HIV transmission (PMTCT). The authors are planning on updating an 'umbrella' review on PMTCT conducted in 2007. The aim of the 2007 'umbrella' review was to assess efficacy of interventions for PMTCT. Since this review was conducted, interventions for PMTCT have largely focused on different ARV regimens. It is now well known that ARVs are the primary strategy used for PMTCT, with recent guidelines recommending lifelong ART for all pregnant/postpartum women. While the 2007 'umbrella' has not been updated, it is unclear what the overall goal of updating the umbrella review is. ART is known to be the most effective intervention. If the authors are interested in understanding risks associated with different ARV regimens/duration; this may be of interest. However, as the protocol is currently written it is unclear why an updated umbrella review is warranted. Additional, specific comments are provided below:

1. In abstract there are details about the search criteria that are not provided in the manuscript main text. These should be included.
2. In the abstract strengths/limitations a bullet list is provided, but the authors do not specify which are strengths vs. limitations. It is not clear in this section what systematic reviews are included; only new ones since Cochrane? This bullet is confusing due to the wording.

INTRODUCTION

1. The reference in the first sentence is outdated; there are now 2015 and 2016 data available. Also the date on the reference is incorrect (2006).
2. The background lists different interventions that were summarized in the umbrella review, and states that ARVs may also be effective if given to exposed infants. If this is part of the protocol (infant ARV exposure) this should be more clearly specified in the methodology.
3. A stronger justification for why this review should be conducted needs to be proposed. Just stating that it has been a long time since the last review is not sufficient. Please clarify what new analyses or intervention types, etc you plan to include in the review.

OBJECTIVES - this is vague. Be more specific about what the objectives are.

METHODS

1. Inclusion criteria should already be developed for the protocol; they should not be decided after starting the review. Please clarify inclusion criteria a priori.
2. Too much detail on descriptions of existing tools are presented (GRADE, AMSTAR, Support collaboration). These should just be stated that they are used and then referenced. The bulk of the methods constitutes summaries of these tools, and is not necessary. More of the methods should be presented: search terms that will be used, details on statistical analyses (some presented in abstract but not in manuscript methods), and sub-group analyses. Very few details on the analyses are actually presented.

Reviewer: 2

Reviewer Name: Euphemia L. Sibanda

Institution and Country: Centre for Sexual Health & HIV AIDS Research (CeSHHAR) Zimbabwe, Zimbabwe

Competing Interests: None declared

The authors present a protocol paper for a study that will help readers have a quick overview of the evidence of what works in preventing mother to child transmission of HIV.

Comments

1. In the introduction section, authors may need to acknowledge that at the moment there is general clarity/consensus of what works (e.g. the current WHO PMTCT guidelines), and make it clear that this paper is important in so far as it helps collate all evidence into one place for easy reference
2. Page 12 Line 20 and 22 : the description of the search strategy needs to be clearer. How will the search strategy be built? How will search terms be determined; will subject heading searches be done? etc
3. From line 40: the paragraph title is "Strengths and limitations" but no limitations are given
4. Page 10 Line 20 and 22 – it is not clear why reviews which were included in the previous umbrella review are being excluded; it may be useful to synthesize all the evidence together

Minor comments:

5. Page 11 Line 46: repeat of the outcome "still birth"
6. Page 11 Line 52: Not clear what is meant by "assistance to subsequent ARVs"
7. Page 13 lines 37-43, not clear what the sentence starting with "We will assess the published..." means
8. Page 15 line 11 Could change this paragraph title to "Methodological quality of included reviews"
9. The paper may benefit from (grammatical) review of written English

Prof. Charles Wiysonge <Charles.Wiysonge@mrc.ac.za>

Wed, Jan 11, 2017 at 12:07 PM

To: "wwariki@gmail.com" <wwariki@gmail.com>, "wwariki@yahoo.com" <wwariki@yahoo.com>

Cc: "ota@slcn.ac.jp" <ota@slcn.ac.jp>, "rintaromori@gmail.com" <rintaromori@gmail.com>, Nosiselo Mchiza <Nosiselo.Mchiza@mrc.ac.za>, "Hacsi.Horvath@ucsf.edu" <Hacsi.Horvath@ucsf.edu>, "Jennifer.Read@ucsf.edu" <Jennifer.Read@ucsf.edu>

Dear Dr Wariki,

Happy New Year.

Congratulations, the comments below seem very minor.

Here is a link to the protocol of a Cochrane overview of systematic reviews <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011084/epdf>

You may find this useful in revising the manuscript.

Best wishes,

Charles

Professor Charles Shey Wiysonge, MD, MPhil, PhD, MASSAf
Director: Cochrane South Africa

South African Medical Research Council

Tel: +27 21 9380804
Francie van Zijl Drive, Parow Valley | Cape Town | Western Cape
www.samrc.ac.za



Disclaimer - The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful. This email has been automatically archived by Mimecast SA (Pty) Ltd This e-mail and its contents are subject to the South African Medical Research Council e-mail legal notice available at. <http://www.mrc.ac.za/about/EmailLegalNotice.htm>

[Quoted text hidden]

Windy Wariki <wwariki@gmail.com> Wed, Jan 11, 2017 at 10:57 PM
To: "Prof.Charles Wiysonge" <Charles.Wiysonge@mrc.ac.za>
Cc: "wwariki@yahoo.com" <wwariki@yahoo.com>, "ota@slcn.ac.jp" <ota@slcn.ac.jp>, "rintaromori@gmail.com" <rintaromori@gmail.com>, Nosicelo Mchiza <Nosicelo.Mchiza@mrc.ac.za>, "Hacsi.Horvath@ucsf.edu" <Hacsi.Horvath@ucsf.edu>, "Jennifer.Read@ucsf.edu" <Jennifer.Read@ucsf.edu>, read@post.harvard.edu, read_md@verizon.net

Dear Prof. Charles Wiysonge,

Happy New Year, and wish you all the very best.

Congratulations to all of us.

Anyway, thank you very much for sharing the link of protocol of an overview of systematic reviews. I would like to revise the manuscript on the basis of reviewers' comments, and will share the revision to all of you before submission.

Sincerely yours,

Windy Wariki

On 1/11/17, Prof.Charles Wiysonge <Charles.Wiysonge@mrc.ac.za> wrote:

> Dear Dr Wariki,
> Happy New Year.
> Congratulations, the comments below seem very minor.
> Here is a link to the protocol of a Cochrane overview of systematic reviews
> <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011084/epdf>
> You may find this useful in revising the manuscript.
> Best wishes,
> Charles

>
> Professor Charles Shey Wiysonge, MD, MPhil, PhD, MASSAf
> Director: Cochrane South Africa
> South African Medical Research Council
> Tel: +27 21 9380804
> Francie van Zijl Drive, Parow Valley | Cape Town | Western Cape
> www.samrc.ac.za<<http://www.samrc.ac.za>>
> [cid:image001.jpg@01D12B91.C902C7F0]

[Quoted text hidden]

> <https://mc.manuscriptcentral.com/bmjopen><<https://mc.manuscriptcentral.com/bmjopen>>

> and enter your Author Center, where you will find your manuscript title listed under "Manuscripts with Decisions." Under "Actions," click on "Create a Revision." Your manuscript number has been appended to denote a revision.

>
> You may also click the below link to start the revision process (or continue the process if you have already started your revision) for your manuscript.
> If you use the below link you will not be required to login to ScholarOne Manuscripts.

>
> *** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. ***

> https://mc.manuscriptcentral.com/bmjopen?URL_MASK=7454362144674380b4d3434862e66609<https://mc.manuscriptcentral.com/bmjopen?URL_MASK=7454362144674380b4d3434862e66609>

[Quoted text hidden]

> esucksmith@bmj.com<<mailto:esucksmith@bmj.com>>

> Editorial Requests:

> - Please add 1 or 2 limitations to the 'Strengths and Limitations' section

> on pages 4-5. This section should contain up to five short bullet points, no
> longer than one sentence each, that ideally relate to the methods of the
> study reported (see:
> <http://bmjopen.bmj.com/site/about/guidelines.xhtml#articletypes><<http://bmjopen.bmj.com/site/about/guidelines.xhtml#articletypes>>).
>
> - Please improve the reporting of your methods e.g. what dates will the
> literature be searched? What key terms will be used? Please include a draft
> of the full search strategy for at least one database as a supplementary
> file.
>
> - Please include an 'ethics and dissemination' section after the methods and
> analysis, as per journal requirements for study protocols (see:
> <http://bmjopen.bmj.com/site/about/guidelines.xhtml#studyprotocols><<http://bmjopen.bmj.com/site/about/guidelines.xhtml#studyprotocols>>).
>
> - Along with your revised manuscript, please provide a completed copy of the
> PRISMA-P checklist
> (<http://www.prisma-statement.org/documents/PRISMA-P-checklist.pdf><<http://www.prisma-statement.org/documents/PRISMA-P-checklist.pdf>>).

[Quoted text hidden]

postmaster@ucsf.edu <postmaster@ucsf.edu>
To: wwariki@gmail.com

Wed, Jan 11, 2017 at 11:05 PM

Delivery has failed to these recipients or groups:

Hacsi.Horvath@ucsf.edu (Hacsi.Horvath@ucsf.edu)

The recipient's e-mail system isn't accepting messages now. Please try resending this message later or contact the recipient directly.

Diagnostic information for administrators:

Generating server: ucsf.edu

Hacsi.Horvath@ucsf.edu

#550 4.3.2 QUEUE.Admin; message deleted by administrative action ##rfc822;Hacsi.Horvath@ucsf.edu

Original message headers:

Received: from bcuda2.ucsf.edu (64.54.247.193) by exht04.net.ucsf.edu (64.54.247.221) with Microsoft SMTP Server (TLS) id 14.3.319.2; Wed, 11 Jan 2017 06:57:55 -0800
X-ASG-Debug-ID: 1484146673-0a8b7b1b8e18ab50001-iF1P0X
Received: from mail-yw0-f173.google.com (mail-yw0-f173.google.com [209.85.161.173]) by bcuda2.ucsf.edu with ESMTMP id 5k6wnA0A2BUtzgbF (version=TLSv1.2 cipher=ECDHE-RSA-AES128-GCM-SHA256 bits=128 verify=NO); Wed, 11 Jan 2017 06:57:54 -0800 (PST)
X-Barracuda-Envelope-From: wwariki@gmail.com
X-Barracuda-Effective-Source-IP: mail-yw0-f173.google.com[209.85.161.173]
X-Barracuda-Apparent-Source-IP: 209.85.161.173
Received: by mail-yw0-f173.google.com with SMTP id w75so77298677ywg.1; Wed, 11 Jan 2017 06:57:54 -0800 (PST)
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=gmail.com; s=20161025; h=mime-version:in-reply-to:references:from:date:message-id:subject:to:cc:content-transfer-encoding; bh=8NzG+/FDYvGjT7Jt2WE8X7dpJl5MyoEh0+nPYySIDMo=; b=mnvDht3pnVmkFgNkM0w5++6Xr49DC3c6xbKlcfz1ArYz//VmT6zcgRL8ZiurAtkZv1x1QPk6kMY8KYR6M0IRt22rZXgRionNV2N6FDsz78sQqQGKrOZJbBOYgTFpYHLJiXcG6/MtT7hlqT/gQK+maYpJnf5khpbb0IveHyfNy7WsgOfFXA4GTN0c1/qWjwPE6Sf3nUxwIB79M3FuT2Mt7wxF7HzIzK6Hek85jOU97EapmitORGS6E1tf3sqBanOT80cCqe5DZUxfYX9Z7yui9ryq2sqk05UlydWDtSm78t3eEMA8TIpxXOegyAM96UaoHHJlPsepLfl1t5nppPYz3Zw==
X-Google-DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=1e100.net; s=20161025; h=x-gm-message-state:mime-version:in-reply-to:references:from:date:message-id:subject:to:cc:content-transfer-encoding; bh=8NzG+/FDYvGjT7Jt2WE8X7dpJl5MyoEh0+nPYySIDMo=; b=FPd18P429afQKj9UipsMtLfIvDEgwyY00BPa7qDaktaLe4TzPnp6DrdLaNhgk7GEe0yovWJcDGdMXfoxcSfswYCHOmCZemPPcITOK+/09ZqIqV63Xc8Sivj53++FB5Xh4ke0ICN52UaGxL5mjlaukg080fUj11TFfZuhwM0juLiKAjvPyB7kiwX8K8/fHM7/C2TM2Ro+r8pofrRP91B5uJA20lQC12NSp7yMbI2mmGVlJaFQzxx+penNQOPBugg3sLDo26hIaRnzwLEMEvhg3Tfjla0w3qW4GA2q4/P0z62vuXNw6LRjEKNjFzG6/Ymiqc00qRKGkoywbjSoCCTQ==
X-Gm-Message-State: AikVDXKcvm1C8+JRocnQOH8CGWumcW68Ql1KgVk+vkeggX4R7NKgjMMxBC0cPx1prz7qncriweluFMKz4bY7XQ==
X-Received: by 10.129.156.87 with SMTP id t84mr7457406ywg.100.1484146673408; Wed, 11 Jan 2017 06:57:53 -0800 (PST)
MIME-Version: 1.0
Received: by 10.129.82.75 with HTTP; Wed, 11 Jan 2017 06:57:53 -0800 (PST)
In-Reply-To: <a573a228468c4a33abe7c26a09ac37ce@mrc.ac.za>
References: <1808427367.32802.1484058716443@c421ydass1as.int.thomsonreuters.com> <a573a228468c4a33abe7c26a09ac37ce@mrc.ac.za>
From: Windy Wariki <wwariki@gmail.com>

Date: Wed, 11 Jan 2017 22:57:53 +0800

Message-ID: <CA07tpAkdaUzSU54oJcTPKg6Uis=0G5ZpN9Ft=u1Pqd6KSd8-Tw@mail.gmail.com>

Subject: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332

To: Prof.Charles Wiysonge <Charles.Wiysonge@mrc.ac.za>

X-ASG-Orig-Subj: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332

CC: "wwariki@yahoo.com" <wwariki@yahoo.com>, "ota@slcn.ac.jp"

<ota@slcn.ac.jp>, "rintaromori@gmail.com" <rintaromori@gmail.com>, "Nosicelo

Mchiza" <Nosicelo.Mchiza@mrc.ac.za>, "Hacsi.Horvath@ucsf.edu"

<Hacsi.Horvath@ucsf.edu>, "Jennifer.Read@ucsf.edu" <Jennifer.Read@ucsf.edu>,

<read@post.harvard.edu>, <read_md@verizon.net>

Content-Type: text/plain; charset="UTF-8"

Content-Transfer-Encoding: quoted-printable

X-Barracuda-Connect: mail-yw0-f173.google.com[209.85.161.173]

X-Barracuda-Start-Time: 1484146674

X-Barracuda-Encrypted: ECDHE-RSA-AES128-GCM-SHA256

X-Barracuda-URL: https://bcuda2.ucsf.edu:443/cgi-mod/mark.cgi

X-Barracuda-Scan-Msg-Size: 12089

X-Virus-Scanned: by bsmtpd at ucsf.edu

X-Barracuda-BRTS-Status: 1

X-Barracuda-Spam-Score: 0.00

X-Barracuda-Spam-Status: No, SCORE=0.00 using per-user scores of TAG_LEVEL=1000.0 QUARANTINE_LEVEL=3.0

KILL_LEVEL=5.0 tests=BSF_SC0_MISMATCH_TO

X-Barracuda-Spam-Report: Code version 3.2, rules version 3.2.3.35709

Rule breakdown below

pts	rule name	description
-----	-----------	-------------

0.00	BSF_SC0_MISMATCH_TO	Envelope rcpt doesn't match header
------	---------------------	------------------------------------

Return-Path: wwariki@gmail.com

X-PMWin-Version: 3.1.3.0, Antispam-Engine: 2.7.2, Antispam-Data:

2017.1.11.143316, Antivirus-Engine: 3.64.3, Antivirus-Data: 5.35

X-PMWin-Spam: Gauge=IIIIIIIII, Probability=9,

Report='__PHISH_SPEAR_HTTP_RECEIVED 0, __YOUTUBE_RCVD 0, DKIM_SIGNATURE 0,

__MIME_VERSION 0, __IN_REP_TO 0, __REFERENCES 0, __HAS_FROM 0,

__FRAUD_WEBMAIL_FROM 0, __FROM_GMAIL 0, __DATE_TZ_HK 0, __HAS_MSGID 0,

__SANE_MSGID 0, __BOUNCE_CHALLENGE_SUBJ 0, __BOUNCE_NDR_SUBJ_EXEMPT 0,

__TO_MALFORMED_2 0, __TO_NAME 0, __TO_NAME_DIFF_FROM_ACC 0, __HAS_CC_HDR 0,

__MULTIPLE_RCPTS_CC_X2 0, __CC_NAME 0, __CC_NAME_DIFF_FROM_ACC 0, __CT 0,

__CT_TEXT_PLAIN 0, CT_TEXT_PLAIN_UTF8_CAPS 0, __CTE 0,

__FROM_DOMAIN_IN_ANY_CC1 0, __ANY_URI 0, __HTTPS_URI 0, __URI_WITH_PATH 0,

URI_ENDS_IN_HTML 0, __FRAUD_BODY_WEBMAIL 0, __FRAUD_CONTACT_NUM 0,

__FRAUD_WINNER 0, __STOCK_PHRASE_24 0, __CP_NAME_BODY 0, __CP_URI_IN_BODY 0,

__FRAUD_CONTACT_NAME 0, ECARD_KNOWN_DOMAINS 0, __FRAUD_LOC 0, __C230066_P1_5

0, __CP_NOT_1 0, __SUBJ_ALPHA_NEGATE 0, __MULTIPLE_URI_TEXT 0, __URI_IN_BODY

0, __FORWARDED_MSG 0, __NO_HTML_TAG_RAW 0, BODY_SIZE_10000_PLUS 0,

__MIME_TEXT_P1 0, __MIME_TEXT_ONLY 0, __URI_NS 0, HTML_00_01 0.05,

HTML_00_10 0.05, __FRAUD_WEBMAIL 0, WEBMAIL_SOURCE 0, __FRAUD_COMMON 0,

MULTIPLE_RCPTS 0.1, __PHISH_SPEAR_STRUCTURE_1 0, __FROM_DOMAIN_IN_RCPT 0,

FORGED_FROM_GMAIL 0.1, IN_REP_TO 0, __MIME_TEXT_P 0, REFERENCES 0,

MSG_THREAD 0, __TO_REAL_NAMES 0, __CC_REAL_NAMES 0, LEGITIMATE_SIGNS 0'

Original-Recipient: rfc822;Hacsi.Horvath@ucsf.edu

Final-Recipient: rfc822;Hacsi.Horvath@ucsf.edu

Action: failed

Status: 4.3.2

Diagnostic-Code: smtp;550 4.3.2 QUEUE.Admin; message deleted by administrative action

X-Display-Name: Hacsi.Horvath@ucsf.edu

----- Forwarded message -----

From: Windy Wariki <wwariki@gmail.com>

To: "Prof.Charles Wiysonge" <Charles.Wiysonge@mrc.ac.za>

Cc: "wwariki@yahoo.com" <wwariki@yahoo.com>, "ota@slcn.ac.jp" <ota@slcn.ac.jp>, "rintaromori@gmail.com" <rintaromori@gmail.com>, Nosicelo Mchiza <Nosicelo.Mchiza@mrc.ac.za>, "Hacsi.Horvath@ucsf.edu" <Hacsi.Horvath@ucsf.edu>, "Jennifer.Read@ucsf.edu" <Jennifer.Read@ucsf.edu>, <read@post.harvard.edu>, <read_md@verizon.net>

Bcc:

Date: Wed, 11 Jan 2017 22:57:53 +0800

Subject: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332

Dear Prof. Charles Wiysonge,

Happy New Year, and wish you all the very best.

Congratulations to all of us.

Anyway, thank you very much for sharing the link of protocol of an overview of systematic reviews. I would like to revise the manuscript on the basis of reviewers' comments, and will share the revision to all of you before submission.

Sincerely yours,

Windy Wariki

On 1/11/17, Prof.Charles Wiysonge <Charles.Wiysonge@mrc.ac.za> wrote:

> Dear Dr Wariki,

> Happy New Year.

> Congratulations, the comments below seem very minor.

> Here is a link to the protocol of a Cochrane overview of systematic reviews

> <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011084/epdf>

> You may find this useful in revising the manuscript.

> Best wishes,

> Charles

>
>
> Professor Charles Shey Wiysonge, MD, MPhil, PhD, MASSAf
> Director: Cochrane South Africa

> South African Medical Research Council

> Tel: +27 21 9380804

> Francie van Zijl Drive, Parow Valley | Cape Town| Western Cape

> www.samrc.ac.za<<http://www.samrc.ac.za>>

> [cid:image001.jpg@01D12B91.C902C7F0]

> Disclaimer - The information contained in this communication from the sender

> is confidential. It is intended solely for use by the recipient and others

> authorized to receive it. If you are not the recipient, you are hereby

> notified that any disclosure, copying, distribution or taking action in

> relation of the contents of this information is strictly prohibited and may

> be unlawful. This email has been automatically archived by Mimecast SA (Pty)

> Ltd This e-mail and its contents are subject to the South African Medical

> Research Council e-mail legal notice available at.

> <http://www.mrc.ac.za/about/EmailLegalNotice.htm>

>

>

>

>

> From: onbehalfof+info.bmjopen+bmj.com@manuscriptcentral.com

> [<mailto:onbehalfof+info.bmjopen+bmj.com@manuscriptcentral.com>]

> Sent: Tuesday, January 10, 2017 6:32 AM

> To: wwariki@gmail.com; wwariki@yahoo.com

> Cc: wwariki@gmail.com; wwariki@yahoo.com; ota@slcn.ac.jp;

> rintaromori@gmail.com; Prof.Charles Wiysonge <Charles.Wiysonge@mrc.ac.za>;

> Nosiselo Mchiza <Nosiselo.Mchiza@mrc.ac.za>; Hacsi.Horvath@ucsf.edu;

> Jennifer.Read@ucsf.edu

> Subject: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332

>

> 10-Jan-2017

>

> Dear Dr. Wariki,

>

> Manuscript ID bmjopen-2016-014332 entitled "Interventions for preventing

> mother-to-child HIV transmission: Protocol of an overview of systematic

> reviews" which you submitted to BMJ Open, has been reviewed. The comments of

> the reviewers are included at the bottom of this letter.

>

> The reviewers have recommended revisions to your manuscript. Therefore, I

> invite you to respond to the reviewers' comments and revise your manuscript.

> Please remember that the reviewers' comments and the previous drafts of your

> manuscript will be published as supplementary information alongside the

> final version.

>

> In addition to the above, please address the editorial requests towards the

> end of this letter.

>

> To revise your manuscript, log into

> <https://mc.manuscriptcentral.com/bmjopen><<https://mc.manuscriptcentral.com/bmjopen>>

> and enter your Author Center, where you will find your manuscript title

> listed under "Manuscripts with Decisions." Under "Actions," click on "Create

> a Revision." Your manuscript number has been appended to denote a revision.

>

> You may also click the below link to start the revision process (or continue

> the process if you have already started your revision) for your manuscript.

> If you use the below link you will not be required to login to ScholarOne

> Manuscripts.

>

> *** PLEASE NOTE: This is a two-step process. After clicking on the link, you

> will be directed to a webpage to confirm. ***

>

> https://mc.manuscriptcentral.com/bmjopen?URL_MASK=7454362144674380b4d3434862e66609<https://mc.manuscriptcentral.com/bmjopen?URL_MASK=7454362144674380b4d3434862e66609>

> https://mc.manuscriptcentral.com/bmjopen?URL_MASK=7454362144674380b4d3434862e66609>

>

>

> You will be unable to make your revisions on the originally submitted

> version of the manuscript. Instead, revise your manuscript using a word

> processing program and save it on your computer. Please also highlight the

> changes to your manuscript within the document by using the track changes

> mode in MS Word or by using bold or colored text. Once the revised manuscript

> is prepared, you can upload it and submit it through your Author Center.

>

> When submitting your revised manuscript, you will be able to respond to the

> comments made by the reviewer(s) in the space provided. You can use this

> space to document any changes you make to the original manuscript. In order

> to expedite the processing of the revised manuscript, please be as specific

> as possible in your response to the reviewer(s).

>

> You will receive a proof if your article is accepted, but you will be unable

> to make substantial changes to your manuscript, please take this opportunity

> to check the revised submission carefully.

>

> IMPORTANT: Your original files are available to you when you upload your

> revised manuscript. Please delete any redundant files before completing the

> submission.

> Because we are trying to facilitate timely publication of manuscripts
> submitted to BMJ Open, your revised manuscript should be submitted within 28
> days. If it is not possible for you to submit your revision by this date, we
> may have to consider your paper as a new submission.

> Once again, thank you for submitting your manuscript to BMJ Open and I look
> forward to receiving your revision.

> Sincerely,

> Dr Edward Sucksmith
> BMJ Open Managing Editor
> esucksmith@bmj.com<mailto:esucksmith@bmj.com>

> Editorial Requests:

> - Please add 1 or 2 limitations to the 'Strengths and Limitations' section
> on pages 4-5. This section should contain up to five short bullet points, no
> longer than one sentence each, that ideally relate to the methods of the
> study reported (see:
> <http://bmjopen.bmj.com/site/about/guidelines.xhtml#articletypes><<http://bmjopen.bmj.com/site/about/guidelines.xhtml#articletypes>>).

> - Please improve the reporting of your methods e.g. what dates will the
> literature be searched? What key terms will be used? Please include a draft
> of the full search strategy for at least one database as a supplementary
> file.

> - Please include an 'ethics and dissemination' section after the methods and
> analysis, as per journal requirements for study protocols (see:
> <http://bmjopen.bmj.com/site/about/guidelines.xhtml#studyprotocols><<http://bmjopen.bmj.com/site/about/guidelines.xhtml#studyprotocols>>).

> - Along with your revised manuscript, please provide a completed copy of the
> PRISMA-P checklist
> (<http://www.prisma-statement.org/documents/PRISMA-P-checklist.pdf><<http://www.prisma-statement.org/documents/PRISMA-P-checklist.pdf>>).

> Please remember to include the relevant page number(s) from the manuscript
> next to each reporting item or state 'n/a' next to items that are not
> applicable to your study.

> Reviewers' Comments to Author:

> Reviewer: 1

> Reviewer Name: Alison Drake
> Institution and Country: Assistant Professor, University of Washington, USE
> Competing Interests: 'None declared'

> This manuscript describes the protocol the investigators plan to use to
> summarize systematic review on prevention of mother-to-child HIV
> transmission (PMTCT). The authors are planning on updating an 'umbrella'
> review on PMTCT conducted in 2007. The aim of the 2007 'umbrella' review was
> to assess efficacy of interventions for PMTCT. Since this review was
> conducted, interventions for PMTCT have largely focused on different ARV
> regimens. It is now well known that ARVs are the primary strategy used for
> PMTCT, with recent guidelines recommending lifelong ART for all
> pregnant/postpartum women. While the 2007 'umbrella' has not been updated,
> it is unclear what the overall goal of updating the umbrella review is. ART
> is known to be the most effective intervention. If the authors are
> interested in understanding risks associated with different ARV
> regimens/duration; this may be of interest. However, as the protocol is
> currently written it is unclear why an updated umbrella review is warranted.
> Additional, specific comments are provided below:

> 1. In abstract there are details about the search criteria that are not
> provided in the manuscript main text. These should be included.
> 2. In the abstract strengths/limitations a bullet list is provided, but the
> authors do not specify which are strengths vs. limitations. It is not clear
> in this section what systematic reviews are included; only new ones since
> Cochrane? This bullet is confusing due to the wording.

> INTRODUCTION

> 1. The reference in the first sentence is outdated; there are now 2015 and
> 2016 data available. Also the date on the reference is incorrect (2006).
> 2. The background lists different interventions that were summarized in the
> umbrella review, and states that ARVs may also be effective if given to
> exposed infants. If this is part of the protocol (infant ARV exposure) this
> should be more clearly specified in the methodology.
> 3. A stronger justification for why this review should be conducted needs to
> be proposed. Just stating that it has been a long time since the last review
> is not sufficient. Please clarify what new analyses or intervention types,
> etc you plan to include in the review.

> OBJECTIVES - this is vague. Be more specific about what the objectives are.

> METHODS

> 1. Inclusion criteria should already be developed for the protocol; they

> should not be decided after starting the review. Please clarify inclusion
> criteria a priori.
> 2. Too much detail on descriptions of existing tools are presented (GRADE,
> AMSTAR, Support collaboration). These should just be stated that they are
> used and then referenced. The bulk of the methods constitutes summaries of
> these tools, and is not necessary. More of the methods should be presented:
> search terms that will be used, details on statistical analyses (some
> presented in abstract but not in manuscript methods), and sub-group
> analyses. Very few details on the analyses are actually presented.

>
>
> Reviewer: 2
> Reviewer Name: Euphemia L. Sibanda
> Institution and Country: Centre for Sexual Health & HIV AIDS Research
> (CeSHHAR) Zimbabwe, Zimbabwe
> Competing Interests: None declared
>

> The authors present a protocol paper for a study that will help readers have
> a quick overview of the evidence of what works in preventing mother to child
> transmission of HIV.

>
> Comments
> 1. In the introduction section, authors may need to acknowledge that at the
> moment there is general clarity/consensus of what works (e.g. the current
> WHO PMTCT guidelines), and make it clear that this paper is important in so
> far as it helps collate all evidence into one place for easy reference
> 2. Page 12 Line 20 and 22 : the description of the search strategy needs to
> be clearer. How will the search strategy be built? How will search terms be
> determined; will subject heading searches be done? etc
> 3. From line 40: the paragraph title is "Strengths and limitations" but no
> limitations are given
> 4. Page 10 Line 20 and 22 – it is not clear why reviews which were included
> in the previous umbrella review are being excluded; it may be useful to
> synthesize all the evidence together

>
> Minor comments:
> 5. Page 11 Line 46: repeat of the outcome "still birth"
> 6. Page 11 Line 52: Not clear what is meant by "assistance to subsequent
> ARVs"
> 7. Page 13 lines 37-43, not clear what the sentence starting with "We will
> assess the published..." means
> 8. Page 15 line 11 Could change this paragraph title to "Methodological
> quality of included reviews"
> 9. The paper may benefit from (grammatical) review of written English
>

Windy Wariki <wwariki@gmail.com>
To: Rintaro Mori <rintaromori@gmail.com>

Wed, Jan 18, 2017 at 1:12 AM

Dear Prof. Mori,

Happy New Year! Have a promising and fulfilling new year 2017, and bring happiness and success in your life.

Here, I am forwarding the decision of BMJ Open on our protocol of overview of PMTCT, which seems not a major revision. I am now revising this manuscript according to the editorial requests and reviewers' comments. However, a bit difficult for me to respond the editorial request point 2c about search strategy (Please include a [draft of the full search strategy for at least one database as a supplementary file](#)). Because you are an expert in this field, then I would like to ask your help to provide this.

I hope that this will not interfere with your busy schedule.

Thank you very much for your attention and kindness.

Sincerely yours,
Windy Wariki
[Quoted text hidden]

Rintaro Mori <rintaromori@gmail.com>
To: Windy Wariki <wwariki@gmail.com>

Wed, Jan 18, 2017 at 8:34 AM

Dear Windy,
Thank you for your new year's greeting and hope you will have a wonderful year ahead. I will ask our information specialists if they are happy to help. Would you be able to send me the current protocol?
Best wishes,
Rintaro
[Quoted text hidden]

Windy Wariki <wwariki@gmail.com>
To: Rintaro Mori <rintaromori@gmail.com>

Thu, Jan 19, 2017 at 9:16 AM

Dear Prof. Mori,

Thank you very much for your support on the revision of this manuscript.
Please kindly find the current protocol as attached file.

Sincerely yours,
Windy Wariki
[Quoted text hidden]

 **Main document - REVISED.docx**
65K

Rintaro Mori <rintaromori@gmail.com>
To: Windy Wariki <wwariki@gmail.com>

Thu, Jan 19, 2017 at 1:21 PM

Dear Windy,
We will develop a search strategy and get back to you.
[Quoted text hidden]

Windy Wariki <wwariki@gmail.com>
To: Rintaro Mori <rintaromori@gmail.com>

Thu, Jan 19, 2017 at 3:17 PM

Dear Prof. Mori,

Thank you very much for your attention.
I am happy to wait.

Sincerely yours,
Windy Wariki
[Quoted text hidden]

Rintaro Mori <rintaromori@gmail.com>
To: Windy Wariki <wwariki@gmail.com>

Fri, Jan 20, 2017 at 7:57 AM

Dear Windy,

See attached,
[Quoted text hidden]

 **PMTCT for HIV overviwe(MEDLINE strategy protocol ver.).txt**
2K

Windy Wariki <wwariki@gmail.com>
To: Rintaro Mori <rintaromori@gmail.com>

Fri, Jan 20, 2017 at 8:39 AM

Dear Prof. Mori,

Thank you very much for sending the search strategy.
I will complete the revision of manuscript soon, and will distribute
to all authors later.

Sincerely yours,

Windy Wariki
[Quoted text hidden]

Windy Wariki <wwariki@gmail.com>
To: ota@slcn.ac.jp, rintaromori@gmail.com, charles.wiysonge@mrc.ac.za, Nosicelo.Mchiza@mrc.ac.za, Hacsi.Horvath@ucsf.edu,
Jennifer.Read@ucsf.edu, "Jennifer.Read" <Jennifer.Read@hhs.gov>, read@post.harvard.edu, read_md@verizon.net
Cc: wwariki@yahoo.com

Wed, Jan 25, 2017 at 9:51 AM

Dear authors,

Thank you very much for your kindly support in revising the protocol
of overview.

I have completed the revision and prepare all appendixes on the basis
of Editorial and Reviewers' recommendations, including main document,
feedback, a draft of search strategy, and PRISMA-P checklist. Please
kindly find as attached files.

I am going to ask you comments and suggestions, or approval of this
draft by Saturday, January 28th, 2017.

Thank you very much for your attention and cooperation.

Sincerely yours,

Windy Wariki


On 1/10/17, BMJ Open
[Quoted text hidden]

4 attachments

 **Main document - REVISED.docx**
75K

 **Feedback-PMTCT Overview of Protocol.docx**
39K

 **Search strategy MEDLINE (Ovid).docx**
79K

 **PRISMA_P_checklist.doc**
82K

Mail Delivery Subsystem <mailer-daemon@googlemail.com>
To: wwariki@gmail.com

Wed, Jan 25, 2017 at 9:51 AM



Address not found

Your message wasn't delivered because the address **Jennifer.Read@hhs.gov** couldn't be found. Check for typos or unnecessary spaces and try again.

The response from the remote server was:

550 #5.1.0 Address rejected.

Final-Recipient: rfc822; Jennifer.Read@hhs.gov

Action: failed

Status: 5.0.0

Remote-MTA: dns; smtp.ees.hhs.gov. (158.72.139.19, the server for the domain hhs.gov.)

Diagnostic-Code: smtp; 550 #5.1.0 Address rejected.

Last-Attempt-Date: Tue, 24 Jan 2017 17:51:37 -0800 (PST)

----- Forwarded message -----

From: Windy Wariki <wwariki@gmail.com>

To: ota@slcn.ac.jp, rintaromori@gmail.com, charles.wiysonge@mrc.ac.za, Nosicelo.Mchiza@mrc.ac.za, Hacsi.Horvath@ucsf.edu, Jennifer.Read@ucsf.edu, "Jennifer.Read" <Jennifer.Read@hhs.gov>, read@post.harvard.edu, read_md@verizon.net

Cc: wwariki@yahoo.com

Bcc:

Date: Wed, 25 Jan 2017 09:51:34 +0800

Subject: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332

Dear authors,

Thank you very much for your kindly support in revising the protocol of overview.

I have completed the revision and prepare all appendixes on the basis of Editorial and Reviewers' recommendations, including main document, feedback, a draft of search strategy, and PRISMA-P checklist. Please kindly find as attached files.

I am going to ask you comments and suggestions, or approval of this draft by Saturday, January 28th, 2017.

Thank you very much for your attention and cooperation.

Sincerely yours,

Windy Wariki

On 1/10/17, BMJ Open

<onbehalfof+info.bmjopen+bmj.com@manuscriptcentral.com> wrote:

> 10-Jan-2017

>

> Dear Dr. Wariki,

>

> Manuscript ID bmjopen-2016-014332 entitled "Interventions for preventing

> mother-to-child HIV transmission: Protocol of an overview of systematic

> reviews" which you submitted to BMJ Open, has been reviewed. The comments

> of the reviewers are included at the bottom of this letter.

>
> The reviewers have recommended revisions to your manuscript. Therefore, I
> invite you to respond to the reviewers' comments and revise your manuscript.
> Please remember that the reviewers' comments and the previous drafts of your
> manuscript will be published as supplementary information alongside the
> final version.
>
> In addition to the above, please address the editorial requests towards the
> end of this letter.
>
> To revise your manuscript, log into <https://mc.manuscriptcentral.com/bmjopen>
> and enter your Author Center, where you will find your manuscript title
> listed under "Manuscripts with Decisions." Under "Actions," click on
> "Create a Revision." Your manuscript number has been appended to denote a
> revision.
>
> You may also click the below link to start the revision process (or continue
> the process if you have already started your revision) for your manuscript.
> If you use the below link you will not be required to login to ScholarOne
> Manuscripts.
>
> *** PLEASE NOTE: This is a two-step process.

----- Message truncated -----

postmaster@ucsf.edu <postmaster@ucsf.edu>
To: wwariki@gmail.com

Wed, Jan 25, 2017 at 9:55 AM

Delivery has failed to these recipients or groups:

Hacsi.Horvath@ucsf.edu

The recipient's e-mail system isn't accepting messages now. Please try resending this message later or contact the recipient directly.

Diagnostic information for administrators:

Generating server: ucsf.edu

Hacsi.Horvath@ucsf.edu

#550 4.3.2 QUEUE.Admin; message deleted by administrative action ##rfc822;Hacsi.Horvath@ucsf.edu

Original message headers:

Received: from bcuda4.ucsf.edu (64.54.247.193) by exht01.net.ucsf.edu
(64.54.247.218) with Microsoft SMTP Server (TLS) id 14.3.319.2; Tue, 24 Jan
2017 17:51:39 -0800
X-ASG-Debug-ID: 1485309096-0ac91d038c2a300001-iF1P0X
Received: from mail-yw0-f181.google.com (mail-yw0-f181.google.com
[209.85.161.181]) by bcuda4.ucsf.edu with ESMTTP id JqOeEd0CuFJNi7M5
(version=TLSv1.2 cipher=ECDHE-RSA-AES128-GCM-SHA256 bits=128 verify=NO); Tue,
24 Jan 2017 17:51:37 -0800 (PST)
X-Barracuda-Envelope-From: wwariki@gmail.com
X-Barracuda-Effective-Source-IP: mail-yw0-f181.google.com[209.85.161.181]
X-Barracuda-Apparent-Source-IP: 209.85.161.181
Received: by mail-yw0-f181.google.com with SMTP id u68so3089470ywg.0;
Tue, 24 Jan 2017 17:51:37 -0800 (PST)
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed;
d=gmail.com; s=20161025;
h=mime-version:in-reply-to:references:from:date:message-id:subject:to
:cc;
bh=olyB917NHNbJLjFJmyQixRYVjPuEuiAYd40Jhk8yw0o=;
b=Vk7UEV4rr968mmkIHdCTYPZHYSjN1NckPEPy6T+EUPpM+qtTSPKAUjeulthEOkVFsQ
KfWmsbByeiaoXuVXYCcQ0+FAKmuN+Ak6476vPfb6fgRaDGAf43PBE4gPPjIIAqL5vDM
16XBuOSWmIbj6Q0+gicWMI9ceDxnfNlWmQLkoDx7Vcjth3JUCjQfUweuPDEsuck7Vuon
HfQZDf7xNo8+Xl6z56MkReTXXQRUECww0e+t0tnti2DdNjMcz9wveDRmx14nUebRBHIj
CIhevhMgdwGnFHfzv6w6Ycty5ZrmeY+2xOProPUz9yJClH/zVOiOzf+1+TUiq0Ocxau3
lvjw==
X-Google-DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed;
d=1e100.net; s=20161025;
h=x-gm-message-state:mime-version:in-reply-to:references:from:date
:message-id:subject:to:cc;
bh=olyB917NHNbJLjFJmyQixRYVjPuEuiAYd40Jhk8yw0o=;
b=RPMh1chzQjUDZu5TrYnIeGMrwtYb5tzZl0AAFR4EJX7DKZFPvhovDbKh8uFN7UhLFX
qLZ5ptsY4zNkX6fQ1DPXOTNQPc6b/EqftUM40ae0dGls0TwwdsZOP7itNqci0VJCswQ5
xgxuxMsYoA4Ng93att02E6OXqLxCPSTKkz/UTYu/kTshwPSvsBfmXCkHWGqpS0dGZc+g
wadwuePaY8ja+r+065izoPGHoL+I8v2f8Wiv7krZcyDYJzZ01u04DNC6+LL2XprCA7nH
n2yIcn2tA46fjVo+gp+UicizcYcmixN0qM6PTNn8WAQSQUP0FleiNF6EHRTsF2Zfc9sY
V+oQ==
X-Gm-Message-State: AIkVDXKV45wRvG0jmctOaf+L1XwSal+gpyJAMOrI2laq0mteFVhH1p1BhVrV/
/OGUXuxAlLrFQdkNJWwrwHlig==
X-Received: by 10.129.117.85 with SMTP id q82mr27663913ywc.207.1485309096468;

Tue, 24 Jan 2017 17:51:36 -0800 (PST)
MIME-Version: 1.0
Received: by 10.129.196.67 with HTTP; Tue, 24 Jan 2017 17:51:34 -0800 (PST)
In-Reply-To: <1808427367.32802.1484058716443@c421ydas1as.int.thomsonreuters.com>
References: <1808427367.32802.1484058716443@c421ydas1as.int.thomsonreuters.com>
From: Windy Wariki <wwariki@gmail.com>
Date: Wed, 25 Jan 2017 09:51:34 +0800
Message-ID: <CAO7tpAmGJy6-GwZxvaKgdwz0Y2dtJJxNw=Lj0q8_25FooMryNg@mail.gmail.com>
Subject: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332
To: <ota@slcn.ac.jp>, <rintaromori@gmail.com>, <charles.wiysonge@mrc.ac.za>, <Nosicelo.Mchiza@mrc.ac.za>, <Hacsi.Horvath@ucsf.edu>, <Jennifer.Read@ucsf.edu>, Jennifer.Read <Jennifer.Read@hhs.gov>, <read@post.harvard.edu>, <read_md@verizon.net>
X-ASG-Orig-Subj: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332
CC: <wwariki@yahoo.com>
Content-Type: multipart/mixed; boundary="001a1147fbc213d1190546e17923"
X-Barracuda-Connect: mail-yw0-f181.google.com[209.85.161.181]
X-Barracuda-Start-Time: 1485309097
X-Barracuda-Encrypted: ECDHE-RSA-AES128-GCM-SHA256
X-Barracuda-URL: https://bcuda4.ucsf.edu:443/cgi-mod/mark.cgi
X-Barracuda-Scan-Msg-Size: 10126
X-Barracuda-BRTS-Status: 1
X-Virus-Scanned: by bsmtpd at ucsf.edu
X-Barracuda-Spam-Score: 0.00
X-Barracuda-Spam-Status: No, SCORE=0.00 using per-user scores of TAG_LEVEL=1000.0 QUARANTINE_LEVEL=3.0 KILL_LEVEL=5.0 tests=BSF_SC0_MISMATCH_TO
X-Barracuda-Spam-Report: Code version 3.2, rules version 3.2.3.36045
Rule breakdown below
pts rule name description

0.00 BSF_SC0_MISMATCH_TO Envelope rcpt doesn't match header
Return-Path: wwariki@gmail.com
X-PMWin-Version: 3.1.3.0, Antispam-Engine: 2.7.2, Antispam-Data: 2017.1.25.4817, Antivirus-Engine: 3.64.3, Antivirus-Data: 5.35
X-PMWin-Spam: Gauge=IIIIIIIIII, Probability=9,
Report='__PHISH_SPEAR_HTTP_RECEIVED 0, __YOUTUBE_RCVD 0, DKIM_SIGNATURE 0, __MIME_VERSION 0, __IN_REP_TO 0, __REFERENCES 0, __HAS_FROM 0, __FRAUD_WEBMAIL_FROM 0, __FROM_GMAIL 0, __DATE_TZ_HK 0, __HAS_MSGID 0, __SANE_MSGID 0, __BOUNCE_CHALLENGE_SUBJ 0, __BOUNCE_NDR_SUBJ_EXEMPT 0, __TO_MALFORMED_2 0, __TO_NO_NAME 0, __TO_NAME 0, __MULTIPLE_RCPTS_TO_X5 0, __HAS_CC_HDR 0, __CT 0, __CTYPE_HAS_BOUNDARY 0, __CTYPE_MULTIPART 0, __CTYPE_MULTIPART_MIXED 0, __FROM_DOMAIN_IN_ANY_TO1 0, __MIME_TEXT_P2 0, __DOCX_ATTACHED2 0, __HAS_ATTACHMENT1 0, __DOCX_ATTACHED1 0, __ANY_URI 0, __HTTPS_URI 0, __URI_WITH_PATH 0, __STOCK_PHRASE_24 0, __CP_NAME_BODY 0, __CP_URI_IN_BODY 0, __FRAUD_INTRO 0, __FRAUD_CONTACT_NAME 0, __HIGHBITS 0, __FRAUD_LOC 0, __CP_NOT_1 0, __SUBJ_ALPHA_NEGATE 0, __MULTIPLE_URI_TEXT 0, __URI_IN_BODY 0, __FORWARDED_MSG 0, __NO_HTML_TAG_RAW 0, BODY_SIZE_10000_PLUS 0, __HAS_ATTACHMENT2 0, __ATTACHMENT_SIZE_25_50K 0, __MIME_TEXT_P1 0, __URI_NS 0, HTML_00_01 0.05, HTML_00_10 0.05, __PHISH_SPEAR_GREETING 0, __FRAUD_WEBMAIL 0, WEBMAIL_SOURCE 0, __FRAUD_COMMON 0, __HAS_ATTACHMENT 0, MULTIPLE_RCPTS 0.1, __PHISH_SPEAR_STRUCTURE_1 0, __FROM_DOMAIN_IN_RCPT 0, FORGED_FROM_GMAIL 0.1, IN_REP_TO 0, __MIME_TEXT_P 0, REFERENCES 0, MSG_THREAD 0, LEGITIMATE_SIGNS 0, DOCX_ATTACHED 0, OFFICE_ATTACHED 0'
Original-Recipient: rfc822;Hacsi.Horvath@ucsf.edu
Final-Recipient: rfc822;Hacsi.Horvath@ucsf.edu
Action: failed
Status: 4.3.2
Diagnostic-Code: smtp;550 4.3.2 QUEUE.Admin; message deleted by administrative action

----- Forwarded message -----
From: Windy Wariki <wwariki@gmail.com>
To: <ota@slcn.ac.jp>, <rintaromori@gmail.com>, <charles.wiysonge@mrc.ac.za>, <Nosicelo.Mchiza@mrc.ac.za>, <Hacsi.Horvath@ucsf.edu>, <Jennifer.Read@ucsf.edu>, "Jennifer.Read" <Jennifer.Read@hhs.gov>, <read@post.harvard.edu>, <read_md@verizon.net>
Cc: <wwariki@yahoo.com>
Bcc:
Date: Wed, 25 Jan 2017 09:51:34 +0800
Subject: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332
Dear authors,

Thank you very much for your kindly support in revising the protocol of overview.

I have completed the revision and prepare all appendixes on the basis of Editorial and Reviewers' recommendations, including main document, feedback, a draft of search strategy, and PRISMA-P checklist. Please kindly find as attached files.

I am going to ask you comments and suggestions, or approval of this draft by Saturday, January 28th, 2017.

Thank you very much for your attention and cooperation.

Sincerely yours,

Windy Wariki

On 1/10/17, BMJ Open

<onbehalfof+info.bmjopen+bmj.com@manuscriptcentral.com> wrote:

> 10-Jan-2017

>

> Dear Dr. Wariki,

>

> Manuscript ID bmjopen-2016-014332 entitled "Interventions for preventing
> mother-to-child HIV transmission: Protocol of an overview of systematic
> reviews" which you submitted to BMJ Open, has been reviewed. The comments
> of the reviewers are included at the bottom of this letter.

>

> The reviewers have recommended revisions to your manuscript. Therefore, I
> invite you to respond to the reviewers' comments and revise your manuscript.
> Please remember that the reviewers' comments and the previous drafts of your
> manuscript will be published as supplementary information alongside the
> final version.

>

> In addition to the above, please address the editorial requests towards the
> end of this letter.

>

> To revise your manuscript, log into <https://mc.manuscriptcentral.com/bmjopen>
> and enter your Author Center, where you will find your manuscript title
> listed under "Manuscripts with Decisions." Under "Actions," click on
> "Create a Revision." Your manuscript number has been appended to denote a
> revision.

>

> You may also click the below link to start the revision process (or continue
> the process if you have already started your revision) for your manuscript.
> If you use the below link you will not be required to login to ScholarOne
> Manuscripts.

>

> *** PLEASE NOTE: This is a two-step process. After clicking on the link, you
> will be directed to a webpage to confirm. ***

>

> https://mc.manuscriptcentral.com/bmjopen?URL_MASK=7454362144674380b4d3434862e66609

>

>

> You will be unable to make your revisions on the originally submitted
> version of the manuscript. Instead, revise your manuscript using a word
> processing program and save it on your computer. Please also highlight the
> changes to your manuscript within the document by using the track changes
> mode in MS Word or by using bold or colored text. Once the revised manuscript
> is prepared, you can upload it and submit it through your Author Center.

>

> When submitting your revised manuscript, you will be able to respond to the
> comments made by the reviewer(s) in the space provided. You can use this
> space to document any changes you make to the original manuscript. In order
> to expedite the processing of the revised manuscript, please be as specific
> as possible in your response to the reviewer(s).

>

> You will receive a proof if your article is accepted, but you will be unable
> to make substantial changes to your manuscript, please take this opportunity
> to check the revised submission carefully.

>

> IMPORTANT: Your original files are available to you when you upload your
> revised manuscript. Please delete any redundant files before completing the
> submission.

>

> Because we are trying to facilitate timely publication of manuscripts
> submitted to BMJ Open, your revised manuscript should be submitted within 28
> days. If it is not possible for you to submit your revision by this date, we
> may have to consider your paper as a new submission.

>

> Once again, thank you for submitting your manuscript to BMJ Open and I look
> forward to receiving your revision.

>

> Sincerely,

>

> Dr Edward Sucksmith
> BMJ Open Managing Editor
> esucksmith@bmj.com

>

>

> Editorial Requests:

>

> - Please add 1 or 2 limitations to the 'Strengths and Limitations' section
> on pages 4-5. This section should contain up to five short bullet points, no
> longer than one sentence each, that ideally relate to the methods of the
> study reported (see:

> <http://bmjopen.bmj.com/site/about/guidelines.xhtml#articletypes>).

>

> - Please improve the reporting of your methods e.g. what dates will the
> literature be searched? What key terms will be used? Please include a draft
> of the full search strategy for at least one database as a supplementary
> file.

>

> - Please include an 'ethics and dissemination' section after the methods and
> analysis, as per journal requirements for study protocols (see:

> <http://bmjopen.bmj.com/site/about/guidelines.xhtml#studyprotocols>).

>
> - Along with your revised manuscript, please provide a completed copy of the
> PRISMA-P checklist
> (<http://www.prisma-statement.org/documents/PRISMA-P-checklist.pdf>). Please
> remember to include the relevant page number(s) from the manuscript next to
> each reporting item or state 'n/a' next to items that are not applicable to
> your study.

>
>
> Reviewers' Comments to Author:

>
> Reviewer: 1
> Reviewer Name: Alison Drake
> Institution and Country: Assistant Professor, University of Washington, USE
> Competing Interests: 'None declared'

>
> This manuscript describes the protocol the investigators plan to use to
> summarize systematic review on prevention of mother-to-child HIV
> transmission (PMTCT). The authors are planning on updating an 'umbrella'
> review on PMTCT conducted in 2007. The aim of the 2007 'umbrella' review
> was to assess efficacy of interventions for PMTCT. Since this review was
> conducted, interventions for PMTCT have largely focused on different ARV
> regimens. It is now well known that ARVs are the primary strategy used for
> PMTCT, with recent guidelines recommending lifelong ART for all
> pregnant/postpartum women. While the 2007 'umbrella' has not been updated,
> it is unclear what the overall goal of updating the umbrella review is. ART
> is known to be the most effective intervention. If the authors are
> interested in understanding risks associated with different ARV
> regimens/duration; this may be of interest. However, as the protocol is
> currently written it is unclear why an updated umbrella review is warranted.
> Additional, specific comments are provided below:

>
> 1. In abstract there are details about the search criteria that are not
> provided in the manuscript main text. These should be included.
> 2. In the abstract strengths/limitations a bullet list is provided, but the
> authors do not specify which are strengths vs. limitations. It is not clear
> in this section what systematic reviews are included; only new ones since
> Cochrane? This bullet is confusing due to the wording.

>
> INTRODUCTION

> 1. The reference in the first sentence is outdated; there are now 2015 and
> 2016 data available. Also the date on the reference is incorrect (2006).
> 2. The background lists different interventions that were summarized in the
> umbrella review, and states that ARVs may also be effective if given to
> exposed infants. If this is part of the protocol (infant ARV exposure) this
> should be more clearly specified in the methodology.
> 3. A stronger justification for why this review should be conducted needs
> to be proposed. Just stating that it has been a long time since the last
> review is not sufficient. Please clarify what new analyses or intervention
> types, etc you plan to include in the review.

>
> OBJECTIVES - this is vague. Be more specific about what the objectives
> are.

>
> METHODS

> 1. Inclusion criteria should already be developed for the protocol; they
> should not be decided after starting the review. Please clarify inclusion
> criteria a priori.
> 2. Too much detail on descriptions of existing tools are presented (GRADE,
> AMSTAR, Support collaboration). These should just be stated that they are
> used and then referenced. The bulk of the methods constitutes summaries of
> these tools, and is not necessary. More of the methods should be presented:
> search terms that will be used, details on statistical analyses (some
> presented in abstract but not in manuscript methods), and sub-group
> analyses. Very few details on the analyses are actually presented.

>
>
> Reviewer: 2

> Reviewer Name: Euphemia L. Sibanda
> Institution and Country: Centre for Sexual Health & HIV AIDS Research
> (CeSHHAR) Zimbabwe, Zimbabwe
> Competing Interests: None declared





>
> The authors present a protocol paper for a study that will help readers have
> a quick overview of the evidence of what works in preventing mother to child
> transmission of HIV.

>
> Comments

> 1. In the introduction section, authors may need to acknowledge that at the
> moment there is general clarity/consensus of what works (e.g. the current
> WHO PMTCT guidelines), and make it clear that this paper is important in so
> far as it helps collate all evidence into one place for easy reference
> 2. Page 12 Line 20 and 22 : the description of the search strategy needs to
> be clearer. How will the search strategy be built? How will search terms be
> determined; will subject heading searches be done? etc
> 3. From line 40: the paragraph title is "Strengths and limitations" but no
> limitations are given
> 4. Page 10 Line 20 and 22 – it is not clear why reviews which were included

- > in the previous umbrella review are being excluded; it may be useful to
- > synthesize all the evidence together
- >
- > Minor comments:
- > 5. Page 11 Line 46: repeat of the outcome "still birth"
- > 6. Page 11 Line 52: Not clear what is meant by "assistance to subsequent
- > ARVs"
- > 7. Page 13 lines 37-43, not clear what the sentence starting with "We will
- > assess the published..." means
- > 8. Page 15 line 11 Could change this paragraph title to "Methodological
- > quality of included reviews"
- > 9. The paper may benefit from (grammatical) review of written English
- >

4 attachments

-  **Main document - REVISED.docx**
75K
-  **Feedback-PMTCT Overview of Protocol.docx**
39K
-  **Search strategy MEDLINE (Ovid).docx**
79K
-  **PRISMA_P_checklist.doc**
82K

Read <read_md@verizon.net>

Thu, Jan 26, 2017 at 7:53 PM

Reply-To: read@post.harvard.edu

To: wwariki@gmail.com, ota@slcn.ac.jp, rintaromori@gmail.com, charles.wiysonge@mrc.ac.za, Nosiselo.Mchiza@mrc.ac.za,

Hacsi.Horvath@ucsf.edu, Jennifer.Read@ucsf.edu, read@post.harvard.edu

Cc: wwariki@yahoo.com

Hi. I am travelling, so have not had much time to go through this. However, have begun to review this, and will try to complete my review by Saturday (but cannot guarantee this). Please confirm we can have more time to review. I have noticed some problems with English grammar in the revised document, so it cannot be submitted as is. Note that Hacsi Horvath is no longer reachable at the ucsf email address. I can look for her updated email address this weekend.

Jennifer Read

email: read@post.harvard.edu

[Quoted text hidden]

[Quoted text hidden]

- > 3. From line 40: the paragraph title is "Strengths and limitations" but no
- > limitations are given
- > 4. Page 10 Line 20 and 22 "it is not clear why reviews which were included
- > in the previous umbrella review are being excluded; it may be useful to
- > synthesize all the evidence together
- >

> Minor comments:

- > 5. Page 11 Line 46: repeat of the outcome "still birth"
- > 6. Page 11 Line 52: Not clear what is meant by "assistance to subsequent
- > ARVs"
- > 7. Page 13 lines 37-43, not clear what the sentence starting with "We will
- > assess the published" means
- > 8. Page 15 line 11 Could change this paragraph title to "Methodological
- > quality of included reviews"

[Quoted text hidden]

Windy Wariki <wwariki@gmail.com>

Thu, Jan 26, 2017 at 10:12 PM

To: "read@post.harvard.edu" <read@post.harvard.edu>

Cc: "ota@slcn.ac.jp" <ota@slcn.ac.jp>, "rintaromori@gmail.com" <rintaromori@gmail.com>, "charles.wiysonge@mrc.ac.za"

<charles.wiysonge@mrc.ac.za>, "Nosiselo.Mchiza@mrc.ac.za" <Nosiselo.Mchiza@mrc.ac.za>, "Hacsi.Horvath@ucsf.edu"

<Hacsi.Horvath@ucsf.edu>, "Jennifer.Read@ucsf.edu" <Jennifer.Read@ucsf.edu>, "wwariki@yahoo.com" <wwariki@yahoo.com>

Dear Dr. Jennifer Read,

Thank you very much for response.

I am happy to wait your comments, suggestions and edits, and also your information about Dr. Horvath's available e-mail address. The deadline of submission to BMJ Open will be February 8th, 2017.

Thank you very much for your attention.

Sincerely yours,
Windy Wariki

[Quoted text hidden]

postmaster@ucsf.edu <postmaster@ucsf.edu>

Thu, Jan 26, 2017 at 10:15 PM

To: wwariki@gmail.com

Delivery has failed to these recipients or groups:

Hacsi.Horvath@ucsf.edu (Hacsi.Horvath@ucsf.edu)

The recipient's e-mail system isn't accepting messages now. Please try resending this message later or contact the recipient directly.

Diagnostic information for administrators:

Generating server: ucsf.edu

Hacsi.Horvath@ucsf.edu

#550 4.3.2 QUEUE.Admin; message deleted by administrative action ##rfc822;Hacsi.Horvath@ucsf.edu

Original message headers:

Received: from bcuda2.ucsf.edu (64.54.247.193) by exht05.net.ucsf.edu (64.54.247.222) with Microsoft SMTP Server (TLS) id 14.3.319.2; Thu, 26 Jan 2017 06:13:02 -0800

X-ASG-Debug-ID: 1485439980-0a8b7b602c3a7910001-iF1P0X

Received: from mail-pf0-f194.google.com (mail-pf0-f194.google.com [209.85.192.194]) by bcuda2.ucsf.edu with ESMTMP id 3vkIwBkT5sNlzBsr (version=TLSv1.2 cipher=ECDHE-RSA-AES128-GCM-SHA256 bits=128 verify=NO); Thu, 26 Jan 2017 06:13:00 -0800 (PST)

X-Barracuda-Envelope-From: wwariki@gmail.com

X-Barracuda-Effective-Source-IP: mail-pf0-f194.google.com[209.85.192.194]

X-Barracuda-Apparent-Source-IP: 209.85.192.194

Received: by mail-pf0-f194.google.com with SMTP id y143sol6566866pfb.1; Thu, 26 Jan 2017 06:13:00 -0800 (PST)

DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=gmail.com; s=20161025; h=references:mime-version:in-reply-to:content-transfer-encoding:message-id:cc:from:subject:date:to; bh=JuVM4kQb1RPsJUfQmPGPVFVdGTA9s4ZYPxUnrkF8wH8=; b=VGYvWqEJ5tXwxSXVUomz/118RiX7adRiuEcmu9PXYbKDJpYsEOZcItmYh7fCHmuY1Gne4ZgJ36CzmNBBP+CAXtj2PDSvBGQpueWwBKR1LF5gp2bhgzFu4pQrAd8ErLuGXWwhA5Tifv2zUdexE1KKDg7MhiwOOrlF90YC+//07x49l+B1I5QB5kD17gKhumB7gCo/nprzzv1A0/Yrtr1LjcYkTMyAE48gyenLy9hhYbaYb+5xcl0AoPNRoKq5Z54w4KQ94FLHs5dLzQM4a2JI3TGSNRCjA0JymwAR1M+gP6G7qJkO6ApjvYsmEzzOnELh7icjar9NguNoZuClhu/7pg==

X-Google-DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=1e100.net; s=20161025; h=x-gm-message-state:references:mime-version:in-reply-to:content-transfer-encoding:message-id:cc:from:subject:date:to; bh=JuVM4kQb1RPsJUfQmPGPVFVdGTA9s4ZYPxUnrkF8wH8=; b=L5H0mFL7W/kSYdyqJEEqKRqawO3OGknD90d5GOVOJy4TP4AK2OLQDUYHfDUnoA4sILcwY7KEp5YqDbBh5YS0N1APWixEeaXUHwoCsKh0FXVboaO1l+B6rr4+z5WfnVKFggINuu5555BOaI4OCLqHZE78tv5hLArb3c6z4plzVYRzfaGa2Snzyd0QNFvVD0AgYTE2AZLrXE8PLp7heyfs19FBQT8aBBTNN05GwhqvJygnI+wSS6cPREoUofOQow5VQfFI8piZ1X/nSMo3Js8ruilz1GZMYmKRZCiziUGk/JG9j0eJd7g09dJENq/Yk5LsKba2Epfv+cWpPlfR86TkQ==

X-Gm-Message-State: AikVDXLjZoxbKQsVEPJ0QZc26EDRRk7t7H17iwsjcETp+plzUH0dcwR0NchHsCdLSIxOQ==

X-Received: by 10.99.121.78 with SMTP id u75mr3373387pgc.202.1485439980104; Thu, 26 Jan 2017 06:13:00 -0800 (PST)

Received: from [192.168.1.104] ([36.85.220.129]) by smtp.gmail.com with ESMTMPSA id s8sm3969493pfj.30.2017.01.26.06.12.58 (version=TLS1 cipher=ECDHE-RSA-AES128-SHA bits=128/128); Thu, 26 Jan 2017 06:12:59 -0800 (PST)

References: <9168345.4321421.1485431587117.JavaMail.root@vznit170158.mailsvcs.net>

MIME-Version: 1.0 (1.0)

In-Reply-To: <9168345.4321421.1485431587117.JavaMail.root@vznit170158.mailsvcs.net>

Content-Type: multipart/alternative; boundary="Apple-Mail-DB8FCB38-244E-4391-97AA-8909D7FD310E"

Content-Transfer-Encoding: 7bit

Message-ID: <5F3CE247-D86E-4F60-A823-009B1CE2EC7B@gmail.com>

CC: "ota@slcn.ac.jp" <ota@slcn.ac.jp>, "rintaromori@gmail.com" <rintaromori@gmail.com>, "charles.wiysonge@mrc.ac.za" <charles.wiysonge@mrc.ac.za>, "Nosicelo.Mchiza@mrc.ac.za" <Nosicelo.Mchiza@mrc.ac.za>, "Hacsi.Horvath@ucsf.edu" <Hacsi.Horvath@ucsf.edu>, "Jennifer.Read@ucsf.edu" <Jennifer.Read@ucsf.edu>, "wwariki@yahoo.com" <wwariki@yahoo.com>

X-Mailer: iPhone Mail (12H4074d)

From: Windy Wariki <wwariki@gmail.com>

Subject: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332

Date: Thu, 26 Jan 2017 22:12:53 +0800

X-ASG-Orig-Subj: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332

To: "read@post.harvard.edu" <read@post.harvard.edu>

X-Barracuda-Connect: mail-pf0-f194.google.com[209.85.192.194]

X-Barracuda-Start-Time: 1485439980

X-Barracuda-Encrypted: ECDHE-RSA-AES128-GCM-SHA256

X-Barracuda-URL: <https://bcuda2.ucsf.edu:443/cgi-mod/mark.cgi>

X-Barracuda-Scan-Msg-Size: 25376

X-Barracuda-BRTS-Status: 1

X-Virus-Scanned: by bsmtpd at ucsf.edu

X-Barracuda-Spam-Score: 0.00

X-Barracuda-Spam-Status: No, SCORE=0.00 using per-user scores of TAG_LEVEL=1000.0 QUARANTINE_LEVEL=3.0 KILL_LEVEL=5.0 tests=BSF_SC0_MISMATCH_TO, HTML_MESSAGE, MIME_QP_LONG_LINE

X-Barracuda-Spam-Report: Code version 3.2, rules version 3.2.3.36085

Rule breakdown below

pts	rule name	description
0.00	BSF_SC0_MISMATCH_TO	Envelope rcpt doesn't match header
0.00	HTML_MESSAGE	BODY: HTML included in message
0.00	MIME_QP_LONG_LINE	RAW: Quoted-printable line longer than 76 chars

Return-Path: wwariki@gmail.com

X-PMWin-Version: 3.1.3.0, Antispam-Engine: 2.7.2, Antispam-Data: 2017.1.26.135721, Antivirus-Engine: 3.64.3, Antivirus-Data: 5.35
X-PMWin-Spam: Gauge=IIIIIIIIII, Probability=9, Report='__YOUTUBE_RCVD 0, DKIM_SIGNATURE 0, __REFERENCES 0, __MIME_VERSION 0, __IN_REP_TO 0, __CT 0, __CTYPE_MULTIPART_ALT 0, __CTYPE_HAS_BOUNDARY 0, __CTYPE_MULTIPART 0, __CTE 0, __HAS_MSGID 0, __SANE_MSGID 0, __MSGID_APPLEMAIL 0, __HAS_CC_HDR 0, __MULTIPLE_RCPTS_CC_X2 0, __CC_NAME 0, __HAS_X_MAILER 0, __HAS_FROM 0, __FRAUD_WEBMAIL_FROM 0, __FROM_GMAIL 0, __BOUNCE_CHALLENGE_SUBJ 0, __BOUNCE_NDR_SUBJ_EXEMPT 0, __DATE_TZ_HK 0, __TO_MALFORMED_2 0, __TO_NO_NAME 0, __TO_NAME 0, __FROM_DOMAIN_IN_ANY_CC2 0, __MIME_TEXT_P2 0, __MIME_TEXT_H2 0, __ANY_URI 0, __HTTPS_URI 0, __URI_WITH_PATH 0, __FRAUD_BODY_WEBMAIL 0, __STOCK_PHRASE_24 0, __CP_NAME_BODY 0, __PHISH_PHRASE1_B 0, __CP_URI_IN_BODY 0, __FRAUD_INTRO 0, __FRAUD_CONTACT_NAME 0, __FRAUD_LOC 0, __CP_NOT_1 0, __SUBJ_ALPHA_NEGATE 0, __PHISH_SPEAR_ACCOUNT_1 0, SUPERLONG_LINE 0.05, __MULTIPLE_URI_TEXT 0, __URI_IN_BODY 0, __FORWARDED_MSG 0, __NO_HTML_TAG_RAW 0, BODY_SIZE_10000_PLUS 0, BODYTEXT_SIZE_3000_MORE 0, __MIME_TEXT_H1 0, __MIME_TEXT_P1 0, __MIME_HTML 0, __URI_NS 0, HTML_00_01 0.05, HTML_00_10 0.05, __PHISH_SPEAR_GREETING 0, __FRAUD_WEBMAIL 0, __FRAUD_COMMON 0, MULTIPLE_RCPTS 0.1, __FROM_DOMAIN_IN_RCPT 0, FORGED_FROM_GMAIL 0.1, IN_REP_TO 0, __MIME_TEXT_H 0, __MIME_TEXT_P 0, REFERENCES 0, MSG_THREAD 0, LEGITIMATE_SIGNS 0'

Original-Recipient: rfc822:Hacsi.Horvath@ucsf.edu

Final-Recipient: rfc822:Hacsi.Horvath@ucsf.edu

Action: failed

Status: 4.3.2

Diagnostic-Code: smtp;550 4.3.2 QUEUE.Admin; message deleted by administrative action

X-Display-Name: Hacsi.Horvath@ucsf.edu

----- Forwarded message -----

From: Windy Wariki <wwariki@gmail.com>

To: "read@post.harvard.edu" <read@post.harvard.edu>

Cc: "ota@slcn.ac.jp" <ota@slcn.ac.jp>, "rintaromori@gmail.com" <rintaromori@gmail.com>, "charles.wiysonge@mrc.ac.za" <charles.wiysonge@mrc.ac.za>, "Nosicelo.Mchiza@mrc.ac.za" <Nosicelo.Mchiza@mrc.ac.za>, "Hacsi.Horvath@ucsf.edu" <Hacsi.Horvath@ucsf.edu>, "Jennifer.Read@ucsf.edu" <Jennifer.Read@ucsf.edu>, "wwariki@yahoo.com" <wwariki@yahoo.com>

Bcc:

Date: Thu, 26 Jan 2017 22:12:53 +0800

Subject: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332

Dear Dr. Jennifer Read,

Thank you very much for response.

I am happy to wait your comments, suggestions and edits, and also your information about Dr. Horvath's available e-mail address. The deadline of submission to BMJ Open will be February 8th, 2017.

Thank you very much for your attention.

Sincerely yours,

Windy Wariki

On Jan 26, 2017, at 7:53 PM, Read <read_md@verizon.net> wrote:

Hi. I am travelling, so have not had much time to go through this. However, have begun to review this, and will try to complete my review by Saturday (but cannot guarantee this). Please confirm we can have more time to review. I have noticed some problems with English grammar in the revised document, so it cannot be submitted as is. Note that Hacsi Horvath is no longer reachable at the ucsf email address. I can look for her updated email address this weekend.

Jennifer Read

email: read@post.harvard.edu

On 01/24/17, Windy Wariki<wwariki@gmail.com> wrote:

Dear authors,

Thank you very much for your kindly support in revising the protocol of overview.

I have completed the revision and prepare all appendixes on the basis of Editorial and Reviewers' recommendations, including main document, feedback, a draft of search strategy, and PRISMA-P checklist. Please kindly find as attached files.

I am going to ask you comments and suggestions, or approval of this draft by Saturday, January 28th, 2017.

Thank you very much for your attention and cooperation.

Sincerely yours,

Windy Wariki

On 1/10/17, BMJ Open

<onbehalf+info.bmjopen+bmj.com@manuscriptcentral.com> wrote:

> 10-Jan-2017

>

> Dear Dr. Wariki,

>

> Manuscript ID bmjopen-2016-014332 entitled "Interventions for preventing
> mother-to-child HIV transmission: Protocol of an overview of systematic
> reviews" which you submitted to BMJ Open, has been reviewed. The comments
> of the reviewers are included at the bottom of this letter.
>
> The reviewers have recommended revisions to your manuscript. Therefore, I
> invite you to respond to the reviewers' comments and revise your manuscript.
> Please remember that the reviewers' comments and the previous drafts of your
> manuscript will be published as supplementary information alongside the
> final version.
>
> In addition to the above, please address the editorial requests towards the
> end of this letter.
>
> To revise your manuscript, log into <https://mc.manuscriptcentral.com/bmjopen>
> and enter your Author Center, where you will find your manuscript title
> listed under "Manuscripts with Decisions." Under "Actions," click on
> "Create a Revision." Your manuscript number has been appended to denote a
> revision.
>
> You may also click the below link to start the revision process (or continue
> the process if you have already started your revision) for your manuscript.
> If you use the below link you will not be required to login to ScholarOne
> Manuscripts.
>
> *** PLEASE NOTE: This is a two-step process. After clicking on the link, you
> will be directed to a webpage to confirm. ***
>
> https://mc.manuscriptcentral.com/bmjopen?URL_MASK=7454362144674380b4d3434862e66609
>
>
> You will be unable to make your revisions on the originally submitted
> version of the manuscript. Instead, revise your manuscript using a word
> processing program and save it on your computer. Please also highlight the
> changes to your manuscript within the document by using the track changes
> mode in MS Word or by using bold or colored text. Once the revised manuscript
> is prepared, you can upload it and submit it through your Author Center.
>
> When submitting your revised manuscript, you will be able to respond to the
> comments made by the reviewer(s) in the space provided. You can use this
> space to document any changes you make to the original manuscript. In order
> to expedite the processing of the revised manuscript, please be as specific
> as possible in your response to the reviewer(s).
>
> You will receive a proof if your article is accepted, but you will be unable
> to make substantial changes to your manuscript, please take this opportunity
> to check the revised submission carefully.
>
> IMPORTANT: Your original files are available to you when you upload your
> revised manuscript. Please delete any redundant files before completing the
> submission.
>
> Because we are trying to facilitate timely publication of manuscripts
> submitted to BMJ Open, your revised manuscript should be submitted within 28
> days. If it is not possible for you to submit your revision by this date, we
> may have to consider your paper as a new submission.
>
> Once again, thank you for submitting your manuscript to BMJ Open and I look
> forward to receiving your revision.
>
> Sincerely,
>
> Dr Edward Sucksmith
> BMJ Open Managing Editor
> esucksmith@bmj.com
>
>
> Editorial Requests:
>
> - Please add 1 or 2 limitations to the 'Strengths and Limitations' section
> on pages 4-5. This section should contain up to five short bullet points, no
> longer than one sentence each, that ideally relate to the methods of the
> study reported (see:
> <http://bmjopen.bmj.com/site/about/guidelines.xhtml#articletypes>).
>
> - Please improve the reporting of your methods e.g. what dates will the
> literature be searched? What key terms will be used? Please include a draft
> of the full search strategy for at least one database as a supplementary
> file.
>
> - Please include an 'ethics and dissemination' section after the methods and
> analysis, as per journal requirements for study protocols (see:
> <http://bmjopen.bmj.com/site/about/guidelines.xhtml#studyprotocols>).
>
> - Along with your revised manuscript, please provide a completed copy of the
> PRISMA-P checklist
> (<http://www.prisma-statement.org/documents/PRISMA-P-checklist.pdf>). Please
> remember to include the relevant page number(s) from the manuscript next to
> each reporting item or state 'n/a' next to items that are not applicable to
> your study.
>
>
> Reviewers' Comments to Author:
>
> Reviewer: 1
> Reviewer Name: Alison Drake

> Institution and Country: Assistant Professor, University of Washington, USE
> Competing Interests: 'None declared'

>

> This manuscript describes the protocol the investigators plan to use to
> summarize systematic review on prevention of mother-to-child HIV
> transmission (PMTCT). The authors are planning on updating an 'umbrella'
> review on PMTCT conducted in 2007. The aim of the 2007 'umbrella' review
> was to assess efficacy of interventions for PMTCT. Since this review was
> conducted, interventions for PMTCT have largely focused on different ARV
> regimens. It is now well known that ARVs are the primary strategy used for
> PMTCT, with recent guidelines recommending lifelong ART for all
> pregnant/postpartum women. While the 2007 'umbrella' has not been updated,
> it is unclear what the overall goal of updating the umbrella review is. ART
> is known to be the most effective intervention. If the authors are
> interested in understanding risks associated with different ARV
> regimens/duration; this may be of interest. However, as the protocol is
> currently written it is unclear why an updated umbrella review is warranted.
> Additional, specific comments are provided below:

>

> 1. In abstract there are details about the search criteria that are not
> provided in the manuscript main text. These should be included.
> 2. In the abstract strengths/limitations a bullet list is provided, but the
> authors do not specify which are strengths vs. limitations. It is not clear
> in this section what systematic reviews are included; only new ones since
> Cochrane? This bullet is confusing due to the wording.

>

> INTRODUCTION

> 1. The reference in the first sentence is outdated; there are now 2015 and
> 2016 data available. Also the date on the reference is incorrect (2006).
> 2. The background lists different interventions that were summarized in the
> umbrella review, and states that ARVs may also be effective if given to
> exposed infants. If this is part of the protocol (infant ARV exposure) this
> should be more clearly specified in the methodology.
> 3. A stronger justification for why this review should be conducted needs
> to be proposed. Just stating that it has been a long time since the last
> review is not sufficient. Please clarify what new analyses or intervention
> types, etc you plan to include in the review.

>

> OBJECTIVES - this is vague. Be more specific about what the objectives
> are.

>

> METHODS

> 1. Inclusion criteria should already be developed for the protocol; they
> should not be decided after starting the review. Please clarify inclusion
> criteria a priori.
> 2. Too much detail on descriptions of existing tools are presented (GRADE,
> AMSTAR, Support collaboration). These should just be stated that they are
> used and then referenced. The bulk of the methods constitutes summaries of
> these tools, and is not necessary. More of the methods should be presented:
> search terms that will be used, details on statistical analyses (some
> presented in abstract but not in manuscript methods), and sub-group
> analyses. Very few details on the analyses are actually presented.

>

>

> Reviewer: 2

> Reviewer Name: Euphemia L. Sibanda

> Institution and Country: Centre for Sexual Health & HIV AIDS Research

> (CeSHHAR) Zimbabwe, Zimbabwe

> Competing Interests: None declared

>

> The authors present a protocol paper for a study that will help readers have
> a quick overview of the evidence of what works in preventing mother to child
> transmission of HIV.

>

> Comments

> 1. In the introduction section, authors may need to acknowledge that at the
> moment there is general clarity/consensus of what works (e.g. the current
> WHO PMTCT guidelines), and make it clear that this paper is important in so
> far as it helps collate all evidence into one place for easy reference
> 2. Page 12 Line 20 and 22 : the description of the search strategy needs to
> be clearer. How will the search strategy be built? How will search terms be
> determined; will subject heading searches be done? etc
> 3. From line 40: the paragraph title is "Strengths and limitations" but no
> limitations are given
> 4. Page 10 Line 20 and 22 "it is not clear why reviews which were included
> in the previous umbrella review are being excluded; it may be useful to
> synthesize all the evidence together

>

> Minor comments:

> 5. Page 11 Line 46: repeat of the outcome "still birth"

> 6. Page 11 Line 52: Not clear what is meant by "assistance to subsequent
> ARVs"

> 7. Page 13 lines 37-43, not clear what the sentence starting with "We will
> assess the published" means

> 8. Page 15 line 11 Could change this paragraph title to "Methodological
> quality of included reviews"

> 9. The paper may benefit from (grammatical) review of written English

>

I am forwarding the following e-mail through this e-mail address, which I got from Prof. Erika Ota.

Thank you very much for your attention.





Sincerely yours,
Windy Wariki

Begin forwarded message:

From: Windy Wariki <wwariki@gmail.com>
Date: January 25, 2017 at 9:51:34 AM GMT+8
To: ota@slcn.ac.jp, rintaromori@gmail.com, charles.wiysonge@mrc.ac.za, Nosiselo.Mchiza@mrc.ac.za, Hacsii.Horvath@ucsf.edu, Jennifer.Read@ucsf.edu, "Jennifer.Read" <Jennifer.Read@hhs.gov>, read@post.harvard.edu, read_md@verizon.net
Cc: wwariki@yahoo.com
Subject: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332

[Quoted text hidden]

4 attachments

-  **Main document - REVISED.docx**
75K
-  **Feedback-PMTCT Overview of Protocol.docx**
39K
-  **Search strategy MEDLINE (Ovid).docx**
79K
-  **PRISMA_P_checklist.doc**
82K

read@post.harvard.edu <read_md@verizon.net> Sat, Jan 28, 2017 at 9:41 PM
To: Windy Wariki <wwariki@gmail.com>, ota@slcn.ac.jp, rintaromori@gmail.com, charles.wiysonge@mrc.ac.za, Nosiselo.Mchiza@mrc.ac.za, Hacsii.Horvath@ucsf.edu, Jennifer.Read@ucsf.edu, "Jennifer.Read" <Jennifer.Read@hhs.gov>, read@post.harvard.edu
Cc: wwariki@yahoo.com, hacsii.horvath@gmail.com

Dear Windy:

Thank you for the opportunity to review.

Please see the 2 attachment - revised main document and revised response to reviewer comments.

- 1). Main document - As the reviewers noted, the document you submitted to the journal for review had errors in English. There must have been some changes to the document AFTER the last version I reviewed before submission to the journal. In any case, I reviewed the document and made revisions to the original wording and to the revised wording that you had prepared in response to the reviewers' comments. NOTE: Once you make the final revisions to the main document, be sure any text that you cite in the response to reviewers' comments matches what is in the final/revised main document.
- 2). Response to reviewer comments - Normally, when responding to reviewer comments from a journal, a LETTER is prepared (NOT a table). The letter has information from the corresponding author in the upper right hand corner, is addressed to the journal editor, begins by thanking the journal editor for the opportunity to respond to reviewer comments, and then lists the comments VERBATIM (with a one-by-one response to each reviewer comment). I usually italicize and bold the text of each response. For example, as follows:
=====

Corresponding author's name, mailing address, and the date of the letter in the upper right hand corne

Name (The Editor) and address of the editor

MANUSCRIPT NUMBER AS ASSIGNED BY THE JOURNAL

Introductory text: Thank you for the opportunity to respond to reviewer comments regarding our manuscript entitled "xxxxx". Please see our responses to these comments below.

Comments from journal editor/editorial staff:

1. Comment 1.....
Response: We agree with this comment, and have revised the text on page x as follows.
2. Comment 2.....
Response: In response to the comment, we have.....

Reviewer 1

1. Comment 1....
Response: xxxxx
2. Comment 2...
Response: xxxxx

We look forward to your review of the revised manuscript and the responses to comments.

Sincerely,

Name of corresponding author


=====

Please confirm receipt of this email message with attachments, and please send all documents submitted to the journal upon submission to the journal. Note that I will be travelling on Monday January 30 - Wednesday February 1, inclusive, with limited email access during this time.

Jennifer

Jennifer Read
Email: read@post.harvard.edu

2 attachments

 **JR revised Jan 28 2017 - main document - Wariki et al -Cochrane.docx**
63K

 **JR revised Jan 28 2017 - Feedback-PMTCT Overview of Protocol.docx**
35K

Windy Wariki <wwariki@gmail.com> Sun, Jan 29, 2017 at 8:53 AM
To: "read@post.harvard.edu" <read_md@verizon.net>
Cc: ota@slcn.ac.jp, rintaromori@gmail.com, charles.wiysonge@mrc.ac.za, Nosicelo.Mchiza@mrc.ac.za, Hacsi.Horvath@ucsf.edu, Jennifer.Read@ucsf.edu, "Jennifer.Read" <Jennifer.Read@hhs.gov>, read@post.harvard.edu, wwariki@yahoo.com, hacsi.horvath@gmail.com

Dear Dr. Jennifer Read,

Thank you very much for your valuable comments and suggestions.
I am going to revise the manuscript on the basis of your comments,
while waiting other authors comments.
I will let you know the final version of manuscript and other
documents, before re-submit to BMJ Open.

Thank you very much for your attention.

Sincerely yours,
Windy Wariki
[Quoted text hidden]

Mail Delivery Subsystem <mailer-daemon@googlemail.com> Sun, Jan 29, 2017 at 8:53 AM
To: wwariki@gmail.com



Address not found

Your message wasn't delivered to **Jennifer.Read@hhs.gov** because the address couldn't be found. Check for typos or unnecessary spaces and try again.

The response from the remote server was:

550 #5.1.0 Address rejected.

Final-Recipient: rfc822; Jennifer.Read@hhs.gov
Action: failed
Status: 5.0.0
Remote-MTA: dns; smtp2.ees.hhs.gov. (158.70.144.146, the server for the domain hhs.gov.)
Diagnostic-Code: smtp; 550 #5.1.0 Address rejected.
Last-Attempt-Date: Sat, 28 Jan 2017 16:53:21 -0800 (PST)

----- Forwarded message -----

From: Windy Wariki <wwariki@gmail.com>
To: "read@post.harvard.edu" <read_md@verizon.net>
Cc: ota@slcn.ac.jp, rintaromori@gmail.com, charles.wiysonge@mrc.ac.za, Nosicelo.Mchiza@mrc.ac.za, Hacsi.Horvath@ucsf.edu, Jennifer.Read@ucsf.edu, "Jennifer.Read" <Jennifer.Read@hhs.gov>, read@post.harvard.edu, wwariki@yahoo.com, hacsi.horvath@gmail.com
Bcc:
Date: Sun, 29 Jan 2017 08:53:20 +0800
Subject: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332
Dear Dr. Jennifer Read,

Thank you very much for your valuable comments and suggestions. I am going to revise the manuscript on the basis of your comments, while waiting other authors comments. I will let you know the final version of manuscript and other documents, before re-submit to BMJ Open.

Thank you very much for your attention.

Sincerely yours,
Windy Wariki

On 1/28/17, read@post.harvard.edu <read_md@verizon.net> wrote:

> Dear Windy:
>
> Thank you for the opportunity to review.
>
> Please see the 2 attachment - revised main document and revised response to reviewer comments.
>
> 1). Main document - As the reviewers noted, the document you submitted to the journal for review had errors in English. There must have been some changes to the document AFTER the last version I reviewed before submission to the journal. In any case, I reviewed the document and made revisions to the original wording and to the revised wording that you had prepared in response to the reviewers' comments. NOTE: Once you make the final revisions to the main document, be sure any text that you cite in the response to reviewers' comments matches what is in the final/revised main document.
>
> 2). Response to reviewer comments - Normally, when responding to reviewer comments from a journal, a LETTER is prepared (NOT a table). The letter has information from the corresponding author in the upper right hand corner, is addressed to the journal editor, begins by thanking the journal editor for the opportunity to respond to reviewer comments, and then lists the comments VERBATIM (with a one-by-one response to each reviewer comment). I usually italicize and bold the text of each response. For example, as follows:
> =====
>
>
> Corresponding author's name, mailing address, and the date of the letter in the upper right hand corne
>
> Name (The Editor) and address of the editor
>

----- Message truncated -----

postmaster@ucsf.edu <postmaster@ucsf.edu>
To: wwariki@gmail.com

Sun, Jan 29, 2017 at 8:55 AM

Delivery has failed to these recipients or groups:

Hacsi.Horvath@ucsf.edu

The recipient's e-mail system isn't accepting messages now. Please try resending this message later or contact the recipient directly.

Diagnostic information for administrators:

Generating server: ucsf.edu

Hacsi.Horvath@ucsf.edu

#550 4.3.2 QUEUE.Admin; message deleted by administrative action ##rfc822;Hacsi.Horvath@ucsf.edu

Original message headers:

Received: from bcuda2.ucsf.edu (64.54.247.193) by EXHT02.net.ucsf.edu (64.54.247.219) with Microsoft SMTP Server (TLS) id 1433.319.2; Sat, 28 Jan 2017 16:53:22 -0800

X-ASG-Debug-ID: 1485651201-0a8b7b389765a80001-iFlP0X

Received: from mail-yw0-f194.google.com (mail-yw0-f194.google.com [209.85.161.194]) by bcuda2.ucsf.edu with ESMTMP id j4ctHYwkAOXcdhzm (version=TLSv1.2 cipher=ECDHE-RSA-AES128-GCM-SHA256 bits=128 verify=NO); Sat, 28 Jan 2017 16:53:22 -0800 (PST)

X-Barracuda-Envelope-From: wwariki@gmail.com

X-Barracuda-Effective-Source-IP: mail-yw0-f194.google.com[209.85.161.194]

X-Barracuda-Apparent-Source-IP: 209.85.161.194

Received: by mail-yw0-f194.google.com with SMTP id v73so27178411ywg.1; Sat, 28 Jan 2017 16:53:22 -0800 (PST)

DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=gmail.com; s=20161025; h=mime-version:in-reply-to:references:from:date:message-id:subject:to:cc; bh=669bDdojI67SVcRs58X7cY4Pr32xEzBzViT49r6hueQ=; b=VopaWR1ISkemNkKHURfhlRSthyeQX+7bDNxeruC4n7jnrvtXYNmLB+h3mqTy0n5XER7OpEameoBTVGhTojMW0UsMKX+IXkqTDxCsWrHkZ7VIVxb/UOJb7jg5SH+TSAul4Gfc3UGzxikBWGMp9Pi/yIckYvxi48scnpfYjEasVeEEHUX1HAgYGFdaEvoiqXldQgJBlJFDu+aavTgrvikveuZzVYGILTY+RnxEj/pEt88KYVaHUy+eCgvo8RalrRca/8a3pRaOO+mvaVluJnD50yOIHgFoXSXX/ZwZvm9c/n0yFGyShFctREYQmksUfDb/qg8rsuCxBpaAOMWpKZJHw==

X-Google-DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=1e100.net; s=20161025; h=x-gm-message-state:mime-version:in-reply-to:references:from:date:message-id:subject:to:cc; bh=669bDdojI67SVcRs58X7cY4Pr32xEzBzViT49r6hueQ=; b=IDNm8qW4ugY/liww2V8zyYBOru+JYa2i8lvTAo04X1js7F6Dks9ovWxeZhkXQS5IfwoCzHuZcHK8CsUKfuIX6+/ygs38zc/ekrW7MTwLdyNSglmRFZeUdzqW6J8+PsaJ/ud5QOy23upyYyasOVA6x7G0UfcgScjQ3a+vFIRogzLwgaTQb5Ia0Tr65AeHKQCi+wcSFSdA1WSsDwq457wqhXmatQ+ma6ntb3vm0+Jh7FVPB6THBaVLS86ReBatpYEAYPMPpE643Naho+9nZlue38nxGREB2+Nf9oNmFHM/UHpY82LZEQK1PrbsbozWAq6WjiBwuzSHcYpElrPo6GDJQ==

X-Gm-Message-State: AikVDXil70ti4/UwVq5ZYmW6kjdjg1Vu4E00do/QEHZz9P3xdfDuAqWl9ItcjB9ebUATWklvx54idBanX6nNQ==

X-Received: by 10.129.117.85 with SMTP id q82mr10108926ywc.207.1485651201383; Sat, 28 Jan 2017 16:53:21 -0800 (PST)

MIME-Version: 1.0

Received: by 10.129.196.67 with HTTP; Sat, 28 Jan 2017 16:53:20 -0800 (PST)

In-Reply-To: <001f01d2796c\$2ae9cd00\$80bd6700\$@verizon.net>

References: <1808427367.32802.1484058716443@c421ydas1as.int.thomsonreuters.com> <CAO7tpAmGJy6-GwZxvaKgdwz0Y2dtJJxNw=Lj0q8_25FooMryNg@mail.gmail.com> <001f01d2796c\$2ae9cd00\$80bd6700\$@verizon.net>

From: Windy Wariki <wwariki@gmail.com>

Date: Sun, 29 Jan 2017 08:53:20 +0800

Message-ID: <CAO7tpA=qm9_tqfdM4C3MX0+z_j42EoZwsk+7ktjrGH8B9YR57Q@mail.gmail.com>

Subject: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332

To: "read@post.harvard.edu" <read_md@verizon.net>

X-ASG-Orig-Subj: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332

CC: <ota@slcn.ac.jp>, <rintaromori@gmail.com>, <charles.wiysonge@mrc.ac.za>, <Nosicelo.Mchiza@mrc.ac.za>, <Hacsi.Horvath@ucsf.edu>, <Jennifer.Read@ucsf.edu>, Jennifer.Read <Jennifer.Read@hhs.gov>, <read@post.harvard.edu>, <wwariki@yahoo.com>, <hacsi.horvath@gmail.com>

Content-Type: text/plain; charset="UTF-8"

X-Barracuda-Connect: mail-yw0-f194.google.com[209.85.161.194]

X-Barracuda-Start-Time: 1485651201

X-Barracuda-Encrypted: ECDHE-RSA-AES128-GCM-SHA256

X-Barracuda-URL: <https://bcuda2.ucsf.edu:443/cgi-mod/mark.cgi>

X-Barracuda-Scan-Msg-Size: 3203

X-Barracuda-BRTS-Status: 1

X-Virus-Scanned: by bsmtpd at ucsf.edu

X-Barracuda-Spam-Score: 0.00

X-Barracuda-Spam-Status: No, SCORE=0.00 using per-user scores of TAG_LEVEL=1000.0 QUARANTINE_LEVEL=3.0 KILL_LEVEL=5.0 tests=BSF_SC0_MISMATCH_TO

X-Barracuda-Spam-Report: Code version 3.2, rules version 3.2.3.36150

pts	rule name	description
0.00	BSF_SC0_MISMATCH_TO	Envelope rcpt doesn't match header

Return-Path: wwariki@gmail.com

X-PMWin-Version: 3.1.3.0, Antispam-Engine: 2.7.2, Antispam-Data: 2017.1.29.915, Antivirus-Engine: 3.64.3, Antivirus-Data: 5.35

X-PMWin-Spam: Gauge=IIIIIIIII, Probability=9, Report='__PHISH_SPEAR_HTTP_RECEIVED 0, __YOUTUBE_RCVD 0, DKIM_SIGNATURE 0, __MIME_VERSION 0, __IN_REP_TO 0, __REFERENCES 0, __HAS_FROM 0, __FRAUD_WEBMAIL_FROM 0, __FROM_GMAIL 0, __DATE_TZ_HK 0, __HAS_MSGID 0, __SANE_MSGID 0, __BOUNCE_CHALLENGE_SUBJ 0, __BOUNCE_NDR_SUBJ_EXEMPT 0, __TO_MALFORMED_2 0, __TO_NO_NAME 0, __TO_NAME 0, __TO_NAME_DIFF_FROM_ACC 0, __HAS_CC_HDR 0, __MULTIPLE_RCPTS_CC_X2 0, __CC_NAME 0, __CT 0, __CT_TEXT_PLAIN 0, CT_TEXT_PLAIN_UTF8_CAPS 0, __FROM_DOMAIN_IN_ANY_CC1 0, __ANY_URI 0, __URI_NO_WWW 0, __PHISH_PHRASE1_A 0, __FRAUD_INTRO 0, __FRAUD_CONTACT_ADDY 0, __INVOICE_MULTILINGUAL 0, __SUBJ_ALPHA_NEGATE 0, __LINES_OF_YELLING 0, __FORWARDED_MSG 0, __NO_HTML_TAG_RAW 0, BODY_SIZE_3000_3999 0, __MIME_TEXT_P1 0, __MIME_TEXT_ONLY 0, __URI_NS 0, HTML_00_01 0.05, HTML_00_10 0.05, __PHISH_SPEAR_GREETING 0, BODY_SIZE_5000_LESS 0, __FRAUD_WEBMAIL 0, WEBMAIL_SOURCE 0, MULTIPLE_RCPTS 0.1, __PHISH_SPEAR_STRUCTURE_1 0, __FROM_DOMAIN_IN_RCPT 0, FORGED_FROM_GMAIL 0.1, IN_REP_TO 0, __PHISH_SPEAR_STRUCTURE_2 0, __MIME_TEXT_P 0, REFERENCES 0, BODY_SIZE_7000_LESS 0, MSG_THREAD 0, __TO_REAL_NAMES 0, LEGITIMATE_SIGNS 0, NO_URI_HTTPS 0'

Original-Recipient: rhc822:Hacsi.Horvath@ucsf.edu

Final-Recipient: rfc822;Hacsi.Horvath@ucsf.edu

Action: failed

Status: 4.3.2

Diagnostic-Code: smtp;550 4.3.2 QUEUE.Admin; message deleted by administrative action

----- Forwarded message -----

From: Windy Wariki <wwariki@gmail.com>

To: "read@post.harvard.edu" <read_md@verizon.net>

Cc: <ota@slcn.ac.jp>, <rintaromori@gmail.com>, <charles.wiysonge@mrc.ac.za>, <Nosicelo.Mchiza@mrc.ac.za>, <Hacsi.Horvath@ucsf.edu>, <Jennifer.Read@ucsf.edu>, "Jennifer.Read" <Jennifer.Read@hhs.gov>, <read@post.harvard.edu>, <wwariki@yahoo.com>, <hacsi.horvath@gmail.com>

Bcc:

Date: Sun, 29 Jan 2017 08:53:20 +0800

Subject: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332

Dear Dr. Jennifer Read,

Thank you very much for your valuable comments and suggestions. I am going to revise the manuscript on the basis of your comments, while waiting other authors comments. I will let you know the final version of manuscript and other documents, before re-submit to BMJ Open.

Thank you very much for your attention.

Sincerely yours,
Windy Wariki

On 1/28/17, read@post.harvard.edu <read_md@verizon.net> wrote:

> Dear Windy:

>
> Thank you for the opportunity to review.

>
> Please see the 2 attachment - revised main document and revised response to reviewer comments.

>
> 1). Main document - As the reviewers noted, the document you submitted to the journal for review had errors in English. There must have been some changes to the document AFTER the last version I reviewed before submission to the journal. In any case, I reviewed the document and made revisions to the original wording and to the revised wording that you had prepared in response to the reviewers' comments. NOTE: Once you make the final revisions to the main document, be sure any text that you cite in the response to reviewers' comments matches what is in the final/revised main document.

>
> 2). Response to reviewer comments - Normally, when responding to reviewer comments from a journal, a LETTER is prepared (NOT a table). The letter has information from the corresponding author in the upper right hand corner, is addressed to the journal editor, begins by thanking the journal editor for the opportunity to respond to reviewer comments, and then lists the comments VERBATIM (with a one-by-one response to each reviewer comment). I usually italicize and bold the text of each response. For example, as follows:

> =====

>
>
> Corresponding author's name, mailing address, and the date of the letter in the upper right hand corne

>
> Name (The Editor) and address of the editor
>
> MANUSCRIPT NUMBER AS ASSIGNED BY THE JOURNAL

>
> Introductory text: Thank you for the opportunity to respond to reviewer comments regarding our manuscript entitled "xxxxx". Please see our responses to these comments below.

>
> Comments from journal editor/editorial staff:

>
> 1. Comment 1.....
> Response: We agree with this comment, and have revised the text on page x as follows.

>
> 2. Comment 2.....
> Response: In response to the comment, we have.....

>
> Reviewer 1

>
> 1. Comment 1....
> Response: xxxxx

>
> 2. Comment 2...
> Response: xxxxx

>
> We look forward to your review of the revised manuscript and the responses to comments.

> Sincerely,
>
> Name of corresponding author
>
> =====
>
> Please confirm receipt of this email message with attachments, and please
> send all documents submitted to the journal upon submission to the journal.
> Note that I will be travelling on Monday January 30 - Wednesday February 1,
> inclusive, with limited email access during this time.
>
> Jennifer
>
> Jennifer Read
> Email: read@post.harvard.edu
>
>
>

ERIKA OTA <ota@slcn.ac.jp> Sun, Jan 29, 2017 at 9:57 AM

To: Windy Wariki <wwariki@gmail.com>
Cc: "read@post.harvard.edu" <read_md@verizon.net>, Rintaro Mori <rintaromori@gmail.com>, charles.wiysonge@mrc.ac.za, Nosicelo.Mchiza@mrc.ac.za, "Horvath, Hacsi" <Hacsi.Horvath@ucsf.edu>, "Read, Jennifer" <Jennifer.Read@ucsf.edu>, "Jennifer.Read" <Jennifer.Read@hhs.gov>, read@post.harvard.edu, windy.wariki@yahoo.com, hacsi.horvath@gmail.com

Dear Windy

Thank you for your hard work. It's great.
My comment attached.

Best wishes

Erika

[Quoted text hidden]

--

.....
Erika Ota, Ph.D., R.N.M.,
Professor
St.Luke's international university
Graduate school of nursing science,
Global Health Nursing
Email: ota@slcn.ac.jp
10-1 Akashicho Chuo-ku Tokyo 104-0044 Japan
Tel: 81-3-3543-6391(Ext)4990
Direct tel: 81-3-5550-2374

 **JR revised Jan 28 2017 - Feedback-PMTCT Overview of Protocol_eo.docx**
42K

Windy Wariki <wwariki@gmail.com> Sun, Jan 29, 2017 at 1:46 PM

To: ERIKA OTA <ota@slcn.ac.jp>
Cc: "read@post.harvard.edu" <read_md@verizon.net>, Rintaro Mori <rintaromori@gmail.com>, charles.wiysonge@mrc.ac.za, Nosicelo.Mchiza@mrc.ac.za, "Horvath, Hacsi" <Hacsi.Horvath@ucsf.edu>, "Read, Jennifer" <Jennifer.Read@ucsf.edu>, "Jennifer.Read" <Jennifer.Read@hhs.gov>, read@post.harvard.edu, windy.wariki@yahoo.com, hacsi.horvath@gmail.com

Dear Prof. Ota,

Thank you very much for your kindly response.
I will revise the manuscript soon, and will send to you before re-submission.

Sincerely yours,

Windy Wariki

[Quoted text hidden]

Mail Delivery Subsystem <mailer-daemon@googlemail.com> Sun, Jan 29, 2017 at 1:46 PM

To: wwariki@gmail.com

[Quoted text hidden]

Final-Recipient: rfc822; Jennifer.Read@hhs.gov
Action: failed
Status: 5.0.0
Remote-MTA: dns; smtp2.ees.hhs.gov. (158.70.144.146, the server for the domain hhs.gov.)
Diagnostic-Code: smtp; 550 #5.1.0 Address rejected.
Last-Attempt-Date: Sat, 28 Jan 2017 21:46:35 -0800 (PST)

----- Forwarded message -----

From: Windy Wariki <wwariki@gmail.com>
To: ERIKA OTA <ota@slcn.ac.jp>
Cc: "read@post.harvard.edu" <read_md@verizon.net>, Rintaro Mori <rintaromori@gmail.com>, charles.wiysonge@mrc.ac.za,

Nosicelo.Mchiza@mrc.ac.za, "Horvath, Hacsii" <Hacsii.Horvath@ucsf.edu>, "Read, Jennifer" <Jennifer.Read@ucsf.edu>, "Jennifer.Read" <Jennifer.Read@hhs.gov>, read@post.harvard.edu, windy wariki <wwariki@yahoo.com>, hacsii.horvath@gmail.com
Bcc:

Date: Sun, 29 Jan 2017 13:46:34 +0800

Subject: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332

Dear Prof. Ota,

Thank you very much for your kindly response.
I will revise the manuscript soon, and will send to you before re-submission.

Sincerely yours,

Windy Wariki

On 1/29/17, ERIKA OTA <ota@slcn.ac.jp> wrote:

> Dear Windy

>
> Thank you for your hard work. It's great.
> My comment attached.

>
> Best wishes
> Erika

>
> 2017-01-29 9:53 GMT+09:00 Windy Wariki <wwariki@gmail.com>:

>> Dear Dr. Jennifer Read,
>>

>> Thank you very much for your valuable comments and suggestions.
>> I am going to revise the manuscript on the basis of your comments,
>> while waiting other authors comments.
>> I will let you know the final version of manuscript and other
>> documents, before re-submit to BMJ Open.

>>
>> Thank you very much for your attention.

>>
>> Sincerely yours,
>> Windy Wariki

>>
>>
>> On 1/28/17, read@post.harvard.edu <read_md@verizon.net> wrote:
>> > Dear Windy:

>> >
>> > Thank you for the opportunity to review.

>> >
>> > Please see the 2 attachment - revised main document and revised
>> > response
>> > to
>> > reviewer comments.

>> >
>> > 1). Main document - As the reviewers noted, the document you submitted

>> > to
>> > the journal for review had errors in English. There must have been
>> > some
>> > changes to the document AFTER the last version I reviewed before
>> > submission
>> > to the journal. In any case, I reviewed the document and made

>> > revisions
>> > to
>> > the original wording and to the revised wording that you had prepared
>> > in
>> > response to the reviewers' comments. NOTE: Once you make the final
>> > revisions to the main document, be sure any text that you cite in the
>> > response to reviewers' comments matches what is in the final/revised
>> > main
>> > document.

>> >
>> > 2). Response to reviewer comments - Normally, when responding to
>> > reviewer
>> > comments from a journal, a LETTER is prepared (NOT a table). The
>> > letter
>> > has
>> > information from the corresponding author in the upper right

----- Message truncated -----

postmaster@ucsf.edu <postmaster@ucsf.edu>
To: wwariki@gmail.com

Sun, Jan 29, 2017 at 1:55 PM

Delivery has failed to these recipients or groups:

Horvath, Hacsii (Hacsii.Horvath@ucsf.edu)

The recipient's e-mail system isn't accepting messages now. Please try resending this message later or contact the recipient directly.

Diagnostic information for administrators:

Generating server: ucsf.edu

Hacsi.Horvath@ucsf.edu

#550 4.3.2 QUEUE.Admin; message deleted by administrative action ##rfc822;Hacsi.Horvath@ucsf.edu

Original message headers:

Received: from bcuda4.ucsf.edu (64.54.247.193) by exht04.net.ucsf.edu (64.54.247.221) with Microsoft SMTP Server (TLS) id 14.3.319.2; Sat, 28 Jan 2017 21:46:35 -0800
X-ASG-Debug-ID: 1485668795-0ac91d371b07160001-iF1P0X
Received: from mail-yb0-f196.google.com (mail-yb0-f196.google.com [209.85.213.196]) by bcuda4.ucsf.edu with ESMTPT id 9P1L91XyQs0gZSD9 (version=TLSv1.2 cipher=ECDHE-RSA-AES128-GCM-SHA256 bits=128 verify=NO); Sat, 28 Jan 2017 21:46:35 -0800 (PST)
X-Barracuda-Envelope-From: wwariki@gmail.com
X-Barracuda-Effective-Source-IP: mail-yb0-f196.google.com[209.85.213.196]
X-Barracuda-Apparent-Source-IP: 209.85.213.196
Received: by mail-yb0-f196.google.com with SMTP id j82so18397382ybg.2; Sat, 28 Jan 2017 21:46:35 -0800 (PST)
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=gmail.com; s=20161025; h=mime-version:in-reply-to:references:from:date:message-id:subject:to:cc:content-transfer-encoding; bh=Cc5fz71Ez4E5JPiAzLwTNNml3OfSyMiWnZLNDwKmKsE=; b=ePlrGf11QDEDW02KxTVjORGkZvcKq61svmIkXVuLSvP4wayE13zv0ezrlcj5K3+DfO36eevRWIXY3HadV4Ar8mhh5A1ILyGo+RCKLitVKXZE0H7SaY5RhDaHc8IpsgSv8iAoUpYXelIyU2qc6utY3vGWrqubOYJ0tmVs4WF+wTExt2Iz3QiMQZ+YdwP355vRWiwpQSg99gyTwWrT/pLznQguYtn++G2o91Lu+EBUrAYzZblnCie7DCSSOpXWQ7YnUBRab1539wefaV VhgchZ3dFEu76WZ4VRYRrGQ3LmjmXsi+t8UdOtWUTpY7175rI7+JIYBT72ATY1WYqtKocjaw==
X-Google-DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=1e100.net; s=20161025; h=x-gm-message-state:mime-version:in-reply-to:references:from:date:message-id:subject:to:cc:content-transfer-encoding; bh=Cc5fz71Ez4E5JPiAzLwTNNml3OfSyMiWnZLNDwKmKsE=; b=Ek9dEhXLUouoQJ0iX5MjczD+HTWv2e/CmnUj1jUVsWg8aTWGQMEJ/15BGZH1CLrFgop+FhhejcsCibfmbBs10LebsdV0NPtGog9P6+c4mrq7w8o2WBQXnsPhQDKNhZhJUbwZwKVALIydbbiw81pYhd4hdrZUZpI2Xgyu3jRS9x6GRHCPQMcrw4+p7LVH1AV5BjaARdVPTs1QGorYT7PjgJ5UmrkCTtCQqyLLaDeUWAFLnnp06Jxkzaev7k3ZYuYoUd/tw4y9SYLBHLzeY4wa0BPckuB7tdsFBijvJENsXU0mOR9XJuNdaQKimoy5rxAL2V/NZKKs1DPb2xLpp3nKQ==
X-Gm-Message-State: AIkVDXL3iLJt0V2SHK+SqRhk9QiCb2Dtt+jAYQazdne2F/bKeMw2RscuDfl4voXgcfBvQgc37V70peMOQXlmww==
X-Received: by 10.37.208.213 with SMTP id h204mr7229358ybg.187.1485668794736; Sat, 28 Jan 2017 21:46:34 -0800 (PST)
MIME-Version: 1.0
Received: by 10.129.196.67 with HTTP; Sat, 28 Jan 2017 21:46:34 -0800 (PST)
In-Reply-To: <CAKk7MwS+JDowp-atHC4chkTjOfXFMbaG4wjt77KOip9QS4Ciyw@mail.gmail.com>
References: <1808427367.32802.1484058716443@c421ydass1as.int.thomsonreuters.com> <CA07tpAmGJy6-GwZxvaKgdwz0Y2dtJJxNw=Lj0q8_25FooMryNg@mail.gmail.com> <001f01d2796c\$2ae9cd00\$80bd6700\$@verizon.net> <CA07tpA=qm9_tqfdM4C3MX0+z_j42EoZwsk+7ktjrGH8B9YR57Q@mail.gmail.com> <CAKk7MwS+JDowp-atHC4chkTjOfXFMbaG4wjt77KOip9QS4Ciyw@mail.gmail.com>
From: Windy Wariki <wwariki@gmail.com>
Date: Sun, 29 Jan 2017 13:46:34 +0800
Message-ID: <CA07tpA=PbqUmVj81Kxi8_nbCPPoYJxU0+25y=hOxJmyJ5YT4Uw@mail.gmail.com>
Subject: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332
To: ERIKA OTA <ota@slcn.ac.jp>
X-ASG-Orig-Subj: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332
CC: "read@post.harvard.edu" <read_md@verizon.net>, Rintaro Mori <rintaromori@gmail.com>, <charles.wiysonge@mrc.ac.za>, <Nosicelo.Mchiza@mrc.ac.za>, "Horvath, Hacsi" <Hacsi.Horvath@ucsf.edu>, "Read, Jennifer" <Jennifer.Read@ucsf.edu>, Jennifer.Read <Jennifer.Read@hhs.gov>, <read@post.harvard.edu>, windy wariki <wwariki@yahoo.com>, <hacsi.horvath@gmail.com>
Content-Type: text/plain; charset="UTF-8"
Content-Transfer-Encoding: quoted-printable
X-Barracuda-Connect: mail-yb0-f196.google.com[209.85.213.196]
X-Barracuda-Start-Time: 1485668795
X-Barracuda-Encrypted: ECDHE-RSA-AES128-GCM-SHA256
X-Barracuda-URL: https://bcuda4.ucsf.edu:443/cgi-mod/mark.cgi
X-Barracuda-Scan-Msg-Size: 4412
X-Virus-Scanned: by bsmtpd at ucsf.edu
X-Barracuda-BRTS-Status: 1
X-Barracuda-Spam-Score: 0.00
X-Barracuda-Spam-Status: No, SCORE=0.00 using per-user scores of TAG_LEVEL=1000.0 QUARANTINE_LEVEL=3.0 KILL_LEVEL=5.0 tests=BSF_SC0_MISMATCH_TO
X-Barracuda-Spam-Report: Code version 3.2, rules version 3.2.3.36154
Rule breakdown below
pts rule name description

0.00 BSF_SC0_MISMATCH_TO Envelope rcpt doesn't match header
Return-Path: wwariki@gmail.com

X-PMWin-Version: 3.1.3.0, Antispam-Engine: 2.7.2, Antispam-Data: 2017.1.29.52717, Antivirus-Engine: 3.64.3, Antivirus-Data: 5.35
X-PMWin-Spam: Gauge=IIIIIIIII, Probability=9,
Report='__PHISH_SPEAR_HTTP_RECEIVED 0, __YOUTUBE_RCVD 0, DKIM_SIGNATURE 0,
__MIME_VERSION 0, __IN_REP_TO 0, __REFERENCES 0, __HAS_FROM 0,
__FRAUD_WEBMAIL_FROM 0, __FROM_GMAIL 0, __DATE_TZ_HK 0, __HAS_MSGID 0,
__SANE_MSGID 0, __BOUNCE_CHALLENGE_SUBJ 0, __BOUNCE_NDR_SUBJ_EXEMPT 0,
__TO_MALFORMED_2 0, __TO_NAME 0, __TO_NAME_DIFF_FROM_ACC 0, __HAS_CC_HDR 0,
__MULTIPLE_RCPTS_CC_X2 0, __CC_NAME 0, __CC_NAME_DIFF_FROM_ACC 0, __CT 0,
__CT_TEXT_PLAIN 0, CT_TEXT_PLAIN_UTF8_CAPS 0, __CTE 0,
__FROM_DOMAIN_IN_ANY_CC1 0, __ANY_URI 0, __FRAUD_BODY_WEBMAIL 0,
__URI_NO_WWW 0, __PHISH_PHRASE1_A 0, __FRAUD_INTRO 0, __FRAUD_CONTACT_ADDY
0, __INVOICE_MULTILINGUAL 0, __SUBJ_ALPHA_NEGATE 0, __FRAUD_REPLY 0,
__INT_PROD_LOC 0, __LINES_OF_YELLING 0, __FORWARDED_MSG 0, __NO_HTML_TAG_RAW
0, BODY_SIZE_4000_4999 0, __MIME_TEXT_P1 0, __MIME_TEXT_ONLY 0, __URI_NS 0,
HTML_00_01 0.05, HTML_00_10 0.05, __PHISH_SPEAR_GREETING 0,
BODY_SIZE_5000_LESS 0, __FRAUD_WEBMAIL 0, WEBMAIL_SOURCE 0, __FRAUD_COMMON
0, MULTIPLE_RCPTS 0.1, __PHISH_SPEAR_STRUCTURE_1 0, __FROM_DOMAIN_IN_RCPT 0,
FORGED_FROM_GMAIL 0.1, IN_REP_TO 0, __PHISH_SPEAR_STRUCTURE_2 0,
__MIME_TEXT_P 0, REFERENCES 0, BODY_SIZE_7000_LESS 0, MSG_THREAD 0,
__TO_REAL_NAMES 0, __CC_REAL_NAMES 0, LEGITIMATE_SIGNS 0, NO_URI_HTTPS 0'

Original-Recipient: rfc822;Hacsi.Horvath@ucsf.edu

Final-Recipient: rfc822;Hacsi.Horvath@ucsf.edu

Action: failed

Status: 4.3.2

Diagnostic-Code: smtp;550 4.3.2 QUEUE.Admin; message deleted by administrative action

X-Display-Name: Horvath, Hacsi

----- Forwarded message -----

From: Windy Wariki <wwariki@gmail.com>

To: ERIKA OTA <ota@slcn.ac.jp>

Cc: "read@post.harvard.edu" <read_md@verizon.net>, Rintaro Mori <rintaromori@gmail.com>, <charles.wiysonge@mrc.ac.za>, <Nosicelo.Mchiza@mrc.ac.za>, "Horvath, Hacsi" <Hacsi.Horvath@ucsf.edu>, "Read, Jennifer" <Jennifer.Read@ucsf.edu>, "Jennifer.Read" <Jennifer.Read@hhs.gov>, <read@post.harvard.edu>, windy wariki <wwariki@yahoo.com>, <hacsi.horvath@gmail.com>

Bcc:

Date: Sun, 29 Jan 2017 13:46:34 +0800

Subject: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332

Dear Prof. Ota,

Thank you very much for your kindly response.

I will revise the manuscript soon, and will send to you before re-submission.

Sincerely yours,

Windy Wariki

On 1/29/17, ERIKA OTA <ota@slcn.ac.jp> wrote:

> Dear Windy

>
> Thank you for your hard work. It's great.
> My comment attached.

>
> Best wishes
> Erika

>
> 2017-01-29 9:53 GMT+09:00 Windy Wariki <wwariki@gmail.com>:

>> Dear Dr. Jennifer Read,

>>
>> Thank you very much for your valuable comments and suggestions.
>> I am going to revise the manuscript on the basis of your comments,
>> while waiting other authors comments.
>> I will let you know the final version of manuscript and other
>> documents, before re-submit to BMJ Open.

>>
>> Thank you very much for your attention.

>>
>> Sincerely yours,

>> Windy Wariki

>> On 1/28/17, read@post.harvard.edu <read_md@verizon.net> wrote:

>> > Dear Windy:

>> > Thank you for the opportunity to review.

>> > Please see the 2 attachment - revised main document and revised

>> > response

>> > to

>> > reviewer comments.

>> > 1). Main document - As the reviewers noted, the document you submitted

>> > to

>> > the journal for review had errors in English. There must have been

>> > some

>> > changes to the document AFTER the last version I reviewed before
>> > submission
>> > to the journal. In any case, I reviewed the document and made
>> > revisions
>> > to
>> > the original wording and to the revised wording that you had prepared
>> > in
>> > response to the reviewers' comments. NOTE: Once you make the final
>> > revisions to the main document, be sure any text that you cite in the
>> > response to reviewers' comments matches what is in the final/revised
>> > main
>> > document.
>> >
>> > 2). Response to reviewer comments - Normally, when responding to
>> > reviewer
>> > comments from a journal, a LETTER is prepared (NOT a table). The
>> > letter
>> > has
>> > information from the corresponding author in the upper right hand
>> > corner, is
>> > addressed to the journal editor, begins by thanking the journal editor
>> > for
>> > the opportunity to respond to reviewer comments, and then lists the
>> > comments
>> > VERBATIM (with a one-by-one response to each reviewer comment). I
>> > usually
>> > italicize and bold the text of each response. For example, as follows:
>> > =====
>> >
>> >
>> > Corresponding author's name, mailing address, and the date of the
>> > letter
>> > in
>> > the upper right hand corne
>> >
>> > Name (The Editor) and address of the editor
>> >
>> > MANUSCRIPT NUMBER AS ASSIGNED BY THE JOURNAL
>> >
>> > Introductory text: Thank you for the opportunity to respond to
>> > reviewer
>> > comments regarding our manuscript entitled "xxxxx". Please see our
>> > responses to these comments below.
>> >
>> > Comments from journal editor/editorial staff:
>> >
>> > 1. Comment 1.....
>> > Response: We agree with this comment, and have revised the text
>> > on page x
>> > as follows.
>> >
>> > 2. Comment 2.....
>> > Response: In response to the comment, we have.....
>> >
>> > Reviewer 1
>> >
>> > 1. Comment 1....
>> > Response: xxxxx
>> >
>> > 2. Comment 2...
>> > Response: xxxxx
>> >
>> > We look forward to your review of the revised manuscript and the
>> > responses
>> > to comments.
>> >
>> > Sincerely,
>> >
>> > Name of corresponding author
>> >
>> > =====
>> >
>> > Please confirm receipt of this email message with attachments, and
>> > please
>> > send all documents submitted to the journal upon submission to the
>> > journal.
>> > Note that I will be travelling on Monday January 30 - Wednesday
>> > February
>> > 1,
>> > inclusive, with limited email access during this time.
>> >
>> >
>> > Jennifer
>> >
>> > Jennifer Read
>> > Email: read@post.harvard.edu
>> >
>> >
>> >
>> >

>
>
>
> --
>
> Erika Ota, Ph.D., R.N.M.,
> Professor
> St.Luke's international university
> Graduate school of nursing science,
> Global Health Nursing
> Email: ota@slcn.ac.jp
> 10-1 Akashicho Chuo-ku Tokyo 104-0044 Japan
> Tel: 81-3-3543-6391(Ext)4990
> Direct tel: 81-3-5550-2374
>

Mon, Jan 30, 2017 at 3:49 PM

ERIKA OTA <ota@slcn.ac.jp>
To: Windy Wariki <wwariki@gmail.com>

----- Forwarded message -----
From: **ERIKA OTA** <ota@slcn.ac.jp>
Date: 2017-01-29 10:57 GMT+09:00
Subject: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332
[Quoted text hidden]

--
.....
大田えりか
聖路加国際大学大学院
看護学研究科 国際看護学
〒104-0044 東京都中央区明石町10-1
[Quoted text hidden]


 **JR revised Jan 28 2017 - Feedback-PMTCT Overview of Protocol_eo.docx**
42K

Mon, Jan 30, 2017 at 3:49 PM

ERIKA OTA <ota@slcn.ac.jp>
To: Windy Wariki <wwariki@gmail.com>

[Quoted text hidden]
[Quoted text hidden]

2 attachments

 **JR revised Jan 28 2017 - main document - Wariki et al -Cochrane.docx**
63K

 **JR revised Jan 28 2017 - Feedback-PMTCT Overview of Protocol.docx**
35K

Thu, Feb 2, 2017 at 5:17 PM

Prof.Charles Wiysonge <Charles.Wiysonge@mrc.ac.za>
To: "read@post.harvard.edu" <read_md@verizon.net>, Windy Wariki <wwariki@gmail.com>, "ota@slcn.ac.jp" <ota@slcn.ac.jp>, "rintaromori@gmail.com" <rintaromori@gmail.com>, Nosiselo Mchiza <Nosiselo.Mchiza@mrc.ac.za>, "Hacsi.Horvath@ucsf.edu" <Hacsi.Horvath@ucsf.edu>, "Jennifer.Read@ucsf.edu" <Jennifer.Read@ucsf.edu>, "Jennifer.Read" <Jennifer.Read@hhs.gov>, "read@post.harvard.edu" <read@post.harvard.edu>
Cc: "wwariki@yahoo.com" <wwariki@yahoo.com>, "hacsi.horvath@gmail.com" <hacsi.horvath@gmail.com>

Dear Windy,
Is it too late for comments. Please find mine attached.
It is a long time since I worked on MTCT of HIV, but I have concerns with the too many outcomes.
Best wishes,
Charles

Charles Wiysonge
Director : South African Cochrane Centre

South African Medical Research Council
Tel: +27 21 9380804 | Cell:
[Francie van Zijl Drive, Parow Valley | Cape Town | Western Cape](mailto:Francie.van.Zijl@samrc.ac.za)
www.samrc.ac.za





Disclaimer - The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful. This email has been automatically archived by Mimecast SA (Pty) Ltd This e-mail and its contents are subject to the South African Medical Research Council e-mail legal notice available at <http://www.samrc.ac.za/about/EmailLegalNotice.htm>.

-----Original Message-----

From: read@post.harvard.edu [mailto:read_md@verizon.net]

Sent: Saturday, January 28, 2017 3:41 PM

To: 'Windy Wariki' <wwariki@gmail.com>; ota@slcn.ac.jp; rintaromori@gmail.com; Prof.Charles Wiysonge <Charles.Wiysonge@mrc.ac.za>; Nosiselo Mchiza <Nosiselo.Mchiza@mrc.ac.za>; Hacsi.Horvath@ucsf.edu; Jennifer.Read@ucsf.edu; 'Jennifer.Read' <Jennifer.Read@hhs.gov>; read@post.harvard.edu

Cc: wwariki@yahoo.com; hacsi.horvath@gmail.com

Subject: RE: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332

[Quoted text hidden]

2 attachments



117020211173113647.jpg
32K

JR revised Jan 28 2017 - main document - Wariki et al -Cochrane - CSW.docx
74K

Windy Wariki <wwariki@gmail.com>

Fri, Feb 3, 2017 at 12:52 PM

To: "Prof.Charles Wiysonge" <Charles.Wiysonge@mrc.ac.za>

Cc: "read@post.harvard.edu" <read_md@verizon.net>, "ota@slcn.ac.jp" <ota@slcn.ac.jp>, "rintaromori@gmail.com" <rintaromori@gmail.com>, Nosiselo Mchiza <Nosiselo.Mchiza@mrc.ac.za>, "Jennifer.Read@ucsf.edu" <Jennifer.Read@ucsf.edu>, "read@post.harvard.edu" <read@post.harvard.edu>, "wwariki@yahoo.com" <wwariki@yahoo.com>, "hacsi.horvath@gmail.com" <hacsi.horvath@gmail.com>

Dear Prof. Charles Wiysonge,

Thank you very much for your comments, edits, and suggestions.
I am going to revise the manuscript upon your comments too, and will send back to you soon before submission to BMJ.

Sincerely yours,

Windy Wariki

On 2/2/17, Prof.Charles Wiysonge <Charles.Wiysonge@mrc.ac.za> wrote:

> Dear Windy,
> Is it too late for comments. Please find mine attached.
> It is a long time since I worked on MTCT of HIV, but I have concerns with
> the too many outcomes.
> Best wishes,
> Charles
>
> Charles Wiysonge
> Director
> South African Cochrane Centre
> South African Medical Research Council
> Tel: +27 21 9380804
> Mobile:
> Charles.Wiysonge@mrc.ac.za
> Francie van Zijl Drive, Parow Valley | Cape Town | Western Cape
> www.mrc.ac.za

[Quoted text hidden]

Windy Wariki <wwariki@gmail.com>

Sun, Feb 5, 2017 at 8:42 PM

To: "Prof.Charles Wiysonge" <Charles.Wiysonge@mrc.ac.za>

Dear Prof. Charles Wiysonge,

Thank you very much for the chance to responses your valuable comments.
I have revised the manuscript upon your comments, and also prepare separate word file as my feedback to your comments.
Please kindly find as attached file.

As for your information, the deadline for re-submission to BMJ Open will be on February 8, 2017. I will be happy if you could send me back your comments or approval before the deadline. Thank you very much.

Sincerely yours,

Windy Wariki


On 2/2/17, Prof.Charles Wiysonge <Charles.Wiysonge@mrc.ac.za> wrote:

> Dear Windy,
> Is it too late for comments. Please find mine attached.
> It is a long time since I worked on MTCT of HIV, but I have concerns with
> the too many outcomes.
> Best wishes,
> Charles
>
> Charles Wiysonge
> Director
> South African Cochrane Centre
> South African Medical Research Council
> Tel: +27 21 9380804
> Mobile:
> Charles.Wiysonge@mrc.ac.za
> Francie van Zijl Drive, Parow Valley | Cape Town | Western Cape
> www.mrc.ac.za

[Quoted text hidden]

2 attachments

 **2nd revision Feb 05 2017 - main document - BMJ Open.docx**
97K

 **Responses to Prof. CW comments.docx**
98K

Windy Wariki <wwariki@gmail.com>

Mon, Feb 6, 2017 at 8:33 AM

To: "Prof.Charles Wiysonge" <Charles.Wiysonge@mrc.ac.za>, "read@post.harvard.edu" <read_md@verizon.net>, ERIKA OTA <ota@slcn.ac.jp>, Erika Ota <otaerika@gmail.com>, Rintaro Mori <rintaromori@gmail.com>, "Read, Jennifer" <Jennifer.Read@ucsf.edu>, "Jennifer.Read" <Jennifer.Read@hhs.gov>, Hacsí Horvath <hacsí.horvath@gmail.com>, Nosiselo Mchiza <Nosiselo.Mchiza@mrc.ac.za>
Cc: Windy Wariki <wwariki@yahoo.com>

Dear authors,

Thank you very much for the opportunity to review our protocol of overview.

Please kindly find the two attachment: 1) 2nd revision of main document; and 2) Letter to editor, which is response to reviewer comments.

This e-mail is also simply reminder that our revision is due on February 8, 2017. Please send your comments or approval for submitting before the deadline.

Thank you very much for your attention and cooperation.

Sincerely yours,

Windy Wariki

On 2/2/17, Prof.Charles Wiysonge <Charles.Wiysonge@mrc.ac.za> wrote:

> Dear Windy,
> Is it too late for comments. Please find mine attached.
> It is a long time since I worked on MTCT of HIV, but I have concerns with
> the too many outcomes.
> Best wishes,
> Charles
>
> Charles Wiysonge
> Director
> South African Cochrane Centre
> South African Medical Research Council
> Tel: +27 21 9380804
> Mobile:
> Charles.Wiysonge@mrc.ac.za
> Francie van Zijl Drive, Parow Valley | Cape Town | Western Cape
> www.mrc.ac.za

[Quoted text hidden]

2 attachments

 **2nd revision Feb 05 2017 - main document - BMJ Open.docx**
97K

 **Letter to Editor.docx**
113K

Mail Delivery Subsystem <mailer-daemon@googlemail.com>

Mon, Feb 6, 2017 at 8:34 AM

To: wwariki@gmail.com

[Quoted text hidden]

Final-Recipient: rfc822; Jennifer.Read@hhs.gov

Action: failed

Status: 5.0.0

Remote-MTA: dns; smtp.ees.hhs.gov. (158.72.139.19, the server for the domain hhs.gov.)
Diagnostic-Code: smtp; 550 #5.1.0 Address rejected.
Last-Attempt-Date: Sun, 05 Feb 2017 16:34:00 -0800 (PST)

----- Forwarded message -----

From: Windy Wariki <wwariki@gmail.com>
To: "Prof.Charles Wiysonge" <Charles.Wiysonge@mrc.ac.za>, "read@post.harvard.edu" <read_md@verizon.net>, ERIKA OTA <ota@slcn.ac.jp>, Erika Ota <otaerika@gmail.com>, Rintaro Mori <rintaromori@gmail.com>, "Read, Jennifer" <Jennifer.Read@ucsf.edu>, "Jennifer.Read" <Jennifer.Read@hhs.gov>, Hacsi Horvath <hacsi.horvath@gmail.com>, Nosicelo Mchiza <Nosicelo.Mchiza@mrc.ac.za>
Cc: Windy Wariki <wwariki@yahoo.com>
Bcc:
Date: Mon, 6 Feb 2017 08:33:57 +0800
Subject: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332
Dear authors,

Thank you very much for the opportunity to review our protocol of overview.

Please kindly find the two attachment: 1) 2nd revision of main document; and 2) Letter to editor, which is response to reviewer comments.

This e-mail is also simply reminder that our revision is due on February 8, 2017. Please send your comments or approval for submitting before the deadline.

Thank you very much for your attention and cooperation.

Sincerely yours,

Windy Wariki

On 2/2/17, Prof.Charles Wiysonge <Charles.Wiysonge@mrc.ac.za> wrote:

> Dear Windy,
> Is it too late for comments. Please find mine attached.
> It is a long time since I worked on MTCT of HIV, but I have concerns with
> the too many outcomes.
> Best wishes,
> Charles
>
> Charles Wiysonge
> Director
> South African Cochrane Centre
> South African Medical Research Council
> Tel: +27 21 9380804
> Mobile:
> Charles.Wiysonge@mrc.ac.za
> Francie van Zijl Drive, Parow Valley | Cape Town | Western Cape
> www.mrc.ac.za
> -----Original Message-----
> From: read_md@verizon.net [mailto:read_md@verizon.net]
> Sent: Saturday, January 28, 2017 3:41 PM
> To: 'Windy Wariki' <wwariki@gmail.com>; ota@slcn.ac.jp;
> rintaromori@gmail.com; Prof.Charles Wiysonge <Charles.Wiysonge@mrc.ac.za>;
> Nosicelo Mchiza <Nosicelo.Mchiza@mrc.ac.za>; Hacsi.Horvath@ucsf.edu;
> Jennifer.Read@ucsf.edu; 'Jennifer.Read' <Jennifer.Read@hhs.gov>;
> read_md@post.harvard.edu
> Cc: wwariki@yahoo.com; hacsi.horvath@gmail.com
> Subject: RE: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332
>
> Dear Windy:
>
> Thank you for the opportunity to review.
>
> Please see the 2 attachment - revised main document and revised response to
> reviewer comments.
>
> 1). Main document - As the reviewers noted, the document you submitted to
> the journal for review had errors in English. There must have been some
> changes to the document AFTER the last version I reviewed before submission
> to the journal.

----- Message truncated -----

read_md@post.harvard.edu <read_md@post.harvard.edu> Mon, Feb 6, 2017 at 9:10 PM
To: Windy Wariki <wwariki@gmail.com>, "Prof.Charles Wiysonge" <Charles.Wiysonge@mrc.ac.za>, ERIKA OTA <ota@slcn.ac.jp>, Erika Ota <otaerika@gmail.com>, Rintaro Mori <rintaromori@gmail.com>, "Read, Jennifer" <Jennifer.Read@ucsf.edu>, "Jennifer.Read" <Jennifer.Read@hhs.gov>, Hacsi Horvath <hacsi.horvath@gmail.com>, Nosicelo Mchiza <Nosicelo.Mchiza@mrc.ac.za>
Cc: Windy Wariki <wwariki@yahoo.com>

Dear Windy:

Thank you for the opportunity to review.

Manuscript:

1. One paragraph on page 15 was highlighted in yellow. Not clear why you did that. I did not remove the yellow highlighting (but this highlighting would need to be removed before submitting to the journal).

2. I made revisions (retained with track changes) and highlighted changes in yellow throughout the document.

Letter:

1. Suggest underlining the word 'Response' throughout the document (currently only bolded and italicized).
2. Suggest putting quotation marks (") around all text that you have included from the revised manuscript.
3. Once you have the manuscript finalized, then you will need to go through the letter and revise (as necessary) the quotations from the manuscript's revised text.
4. I made some revisions to the language you have used in the cover letter - shown with track changes and yellow highlighting.
5. The document needs numbering of the pages.
6. I highlighted the '....' on page 5 of the letter - not clear if you intended this to be retained in the document or not.

Assuming these revisions are incorporated into the documents, I don't need to see the documents again before submission.

Please send me a copy of the documents after you have submitted to the journal.

Thank you -

Jennifer Read

-----Original Message-----

From: Windy Wariki [mailto:wwariki@gmail.com]

[Quoted text hidden]

2 attachments

 **Letter to Editor - JR revised Feb 6 2017.docx**
26K

 **JSR revised - Feb 6, 2017 - BMJ revised overview manuscript.docx**
79K

Windy Wariki <wwariki@gmail.com>

Mon, Feb 6, 2017 at 11:39 PM

To: "read@post.harvard.edu" <read_md@verizon.net>

Cc: "Prof.Charles Wiysonge" <Charles.Wiysonge@mrc.ac.za>, ERIKA OTA <ota@slcn.ac.jp>, Erika Ota <otaerika@gmail.com>, Rintaro Mori <rintaromori@gmail.com>, "Read, Jennifer" <Jennifer.Read@ucsf.edu>, "Jennifer.Read" <Jennifer.Read@hhs.gov>, Hacsí Horvath <hacsi.horvath@gmail.com>, Nosiselo Mchiza <Nosiselo.Mchiza@mrc.ac.za>, Windy Wariki <wwariki@yahoo.com>

Dear Dr. Jennifer,

Thank you very much for your comments, edits and suggestions.

Sure, I will revise the main document and letter to editor before submitting, and will send them to you, too.

Thank you very much.

Sincerely yours,

Windy Wariki

[Quoted text hidden]

Mail Delivery Subsystem <mailer-daemon@googlemail.com>

Mon, Feb 6, 2017 at 11:39 PM

To: wwariki@gmail.com

[Quoted text hidden]

Final-Recipient: rfc822; Jennifer.Read@hhs.gov

Action: failed

Status: 5.0.0

Remote-MTA: dns; smtp2.ees.hhs.gov. (158.70.144.146, the server for the domain hhs.gov.)

Diagnostic-Code: smtp; 550 #5.1.0 Address rejected.

Last-Attempt-Date: Mon, 06 Feb 2017 07:39:45 -0800 (PST)

----- Forwarded message -----

From: Windy Wariki <wwariki@gmail.com>

To: "read@post.harvard.edu" <read_md@verizon.net>

Cc: "Prof.Charles Wiysonge" <Charles.Wiysonge@mrc.ac.za>, ERIKA OTA <ota@slcn.ac.jp>, Erika Ota <otaerika@gmail.com>, Rintaro Mori <rintaromori@gmail.com>, "Read, Jennifer" <Jennifer.Read@ucsf.edu>, "Jennifer.Read" <Jennifer.Read@hhs.gov>, Hacsí Horvath <hacsi.horvath@gmail.com>, Nosiselo Mchiza <Nosiselo.Mchiza@mrc.ac.za>, Windy Wariki <wwariki@yahoo.com>

Bcc:

Date: Mon, 6 Feb 2017 23:39:44 +0800

Subject: Re: BMJ Open - Decision on Manuscript ID bmjopen-2016-014332

Dear Dr. Jennifer,

Thank you very much for your comments, edits and suggestions.

Sure, I will revise the main document and letter to editor before submitting, and will send them to you, too.

Thank you very much.

Sincerely yours,

Windy Wariki

On 2/6/17, read@post.harvard.edu <read_md@verizon.net> wrote:

> Dear Windy:

>
> Thank you for the opportunity to review.

>
> Manuscript:

> 1. One paragraph on page 15 was highlighted in yellow. Not clear why you
> did that. I did not remove the yellow highlighting (but this highlighting
> would need to be removed before submitting to the journal).
> 2. I made revisions (retained with track changes) and highlighted changes
> in yellow throughout the document.

>
> Letter:

> 1. Suggest underlining the word 'Response' throughout the document
> (currently only bolded and italicized).
> 2. Suggest putting quotation marks ("") around all text that you have
> included from the revised manuscript.
> 3. Once you have the manuscript finalized, then you will need to go through
> the letter and revise (as necessary) the quotations from the manuscript's
> revised text.
> 4. I made some revisions to the language you have used in the cover letter
> - shown with track changes and yellow highlighting.
> 5. The document needs numbering of the pages.
> 6. I highlighted the '....' on page 5 of the letter - not clear if you
> intended this to be retained in the document or not.

>
> Assuming these revisions are incorporated into the documents, I don't need
> to see the documents again before submission.

>
> Please send me a copy of the documents after you have submitted to the
> journal.

>
> Thank you -

>
> Jennifer Read

>
> -----Original Message-----

> From: Windy Wariki [mailto:wwariki@gmail.com]

> Sent: Sunday, February 5, 2017 7:34 PM

> To: Prof. Charles Wiysonge <Charles.Wiysonge@mrc.ac.za>;

> read@post.harvard.edu <read_md@verizon.net>; ERIKA OTA <ota@slcn.ac.jp>;

> Erika Ota <otaerika@gmail.com>

----- Message truncated -----